

CHEMIST & DRUGGIST

THE NEWSWEEKLY FOR PHARMACY

IF YOU THINK IBUPROFEN
GELS ALL WORK THE SAME WAY...
LOOK DEEPER.

GEL
FORMULATION
FOR EASY
ABSORPTION

UNIQUE FORMULA
RELIEVES IN MINUTES
AND
LASTS FOR HOURS

UNIQUE PENETRATION
ENHANCERS
CARRY IBUPROFEN FAST TO
THE POINT OF PAIN

DUAL ACTION GEL

LEVO MENTHOL

IBUPROFEN

UNIQUE COOLING
LEVOMENTHOL
TO HELP YOU
FEEL IT WORKING
INSTANTLY

PRESCRIPTION
STRENGTH
IBUPROFEN
FOR POWERFUL
PAIN RELIEF

DEEP PENETRATING
GEL FORMULATION
EFFECTIVELY RELIEVES
PAIN, DISCOMFORT AND
STIFFNESS

No other formula works faster, lasts longer than Deep Relief. So recommend it for muscular aches and pains, backache, rheumatism or every day arthritic pain. Speak to your Laser representative about special deals now or call 01202 780558.

DEEP RELIEF™

DEEP DOWN PAIN RELIEF THAT LASTS FOR HOURS

ABRIDGED PRESCRIBING INFORMATION: Presentation: Deep Relief is a clear, colourless gel containing Ibuprofen Ph. Eur. 5.0% and Levomenthol Ph. Eur. 3.0%. Uses: A topical anti-inflammatory and analgesic for the relief of rheumatic pain, muscular aches, pains and swellings such as strains, sprains and sport injuries. Also for relief of pain of non serious arthritis (P indication only) Legal category: GSL/P. Product licence holder: The Mentholatum Company Limited, East Kilbride, G74 5PE Scotland. PL 0189/0027. Date of information: Nov 2000. FURTHER INFORMATION FROM THE LICENCE HOLDER IS AVAILABLE ON REQUEST.

**Deacon praises
pharmacy input
to NHSiS Plan**

**Lords inquiry calls
for tighter control
on herbal medicine**
**APPG back pharmacy
schemes in hospitals**

**The NHS Plan and the
pharmacy contract**

**Unichem wins Daily
Telegraph customer
services award**



**Update: vitamins of
the water soluble type**

Online at <http://www.dotpharmacy.com/>

This **LITTLE SOLDIER** has a **cough**,
a **NASTY** little **cough...**



...and a Pharmacist with a bottle of Benylin

Benylin has now recruited a little soldier to promote the Benylin Children's range this winter. He'll be campaigning on your behalf in the women's press to bring more and more mums marching into your pharmacy. Not only is the entire Benylin range sugar-free, colour-free and fitted with child-resistant caps, Benylin also passed a recent taste test with other leading children's dry and chesty cough medicines with flying colours. A taste of success that means little soldiers are happy to take their Benylin.



CHEMIST & DRUGGIST

THE NEWSWEEKLY FOR PHARMACY

VOLUME 254 No 6268 141st YEAR OF PUBLICATION ISSN 0009-3033

REGULARS

News	4	On TV Next Week	14
Northern Ireland Notebook	7	Business News	28
Topical Reflections	7	Coming Events	28
Prescription Specialities	10	Classified Advertisements	30
Counterpoints	12	People	34

COMMENT

Ever since the tribal shaman shook his first set of knuckle bones, quack remedies have been with us. It is a testament to people's eternal optimism (or gullibility) that the number is as great today as it probably was when Noah was a lad. Of course, now the packaging is better, and the health claims better informed, even if the outcome of 'treatment' is the same as it ever was. As our knowledge of what constitutes 'wellbeing' grows, so the spread of products claiming to promote health has grown. The public is keen to exploit the benefits that health supplements, and complementary and alternative medicine (CAM), hold out. Many pharmacists have benefited from this consumer trend and would admit to pushing scientific objectivity into the background to meet customer need. But 'caveat emptor' doesn't apply quite so brutally as it used to. Responsible elements in every area of trade attempt to protect consumers from themselves. The Joint Health Claims Initiative (see p6) is just such an exercise and deserves support. The critical Lords inquiry into CAM tackles similar 'grey areas' from a regulatory perspective, and promises to have a more impact (p5). There is already broad support for the licensing of herbal medicines along the lines proposed under the European Union Directive. More controversial will be the proposal that practitioners making specific claims for their ability to treat specific conditions should have evidence above and beyond the placebo effect. Where will this leave many alternative practitioners? Many pharmacists condone homoeopathic medicine on the basis that there is nothing in it and so it can do no direct harm. If it 'works', so much the better! Many complementary therapies also target the whole person (including their state of mind - a key component of much illnesses and frequently overlooked). This is a concept which regulatory systems struggle to deal with. There are no simple solutions here, but overall, much of what the Lords inquiry recommends makes sense.

Pharmacy NHSIS input praised 4

Pharmacy will have a valuable input to NHSIS, says Scottish Health Minister, Susan Deacon

Lords call for herbs controls 5

A Lords committee has raised concerns about the safety and regulation of herbal products

APPG backs pharmacy schemes in hospitals 6

A parliamentary group has highlighted how hospital pharmacists could ensure better use of medicines

Pharmacists targeted in Welsh no-smoking push 8

Welsh Health Promotion Division is seeking the help of pharmacists for a drive against smoking

Supermarket sweep 16

Information Resources looks at how pharmacy health and beauty product sales are performing

Update: The wet ones

Water soluble vitamins B and C are vital for normal physiological functions

Update: No go zone

All pharmacists will ever need to know about counterprescribing for constipation

Update: The Young Ones

Recent guidelines on prescribing unlicensed medicines for children

Only the best will survive 20

A look at the most controversial section of the NHS Plan - changing the pharmacy contract



Analysing SWOT 25

John Kerry looks at SWOT analyses and suggests ways of evaluating them

Unichem comes up trumps for award 28

Unichem has beaten off opposition to win the *Daily Telegraph* Energis Customer Services Award

When Kirit met Tony 29

Day Lewis chief exec Kirit Patel met PM Tony Blair at a Downing Street Seminar



Editor Patrick Grice

MRPharmS

Assistant Editor Guy L'Aimable, BA

News Editor Charles Gladwin MRPharmS

Business Editor Nina Keller-Henman, Dipl Biol

Technical Editor Steve Bremer MRPharmS

Contributing Editor Adrienne de Mont

MRPharmS

Beauty Editor Sarah Thackray

Reporter Vanessa Sherwood MRPharmS

Art Editor Tony Lamb

Production Editor Vanessa Townsend, BA

Production Sub-Editor Lorri Pimlott

Editorial secretary Jan Powis

Editorial (tel): 01732 377487; (fax): 01732 367065; chemdrug@unitedbusinessmedia.com

Price List

Colin Simpson (Controller), Darren Larkin, Maria Locke

Price List (tel): 01732 377407; (fax): 01732 377559

Group Advertisement Manager Julian de Bruxelles

Group Advertisement Executives Quentin Soldan, Sophie Wellsted

Classified Executive Debra Thackeray

Advertisement department secretary Elaine Steele

Advertising (tel): 01732 377621; (fax): 01732 377179

Production Katrina Avery

Publishing director Fergus Wilson

Associate Publisher John Skelton FRPharmS

© United Business Media Ltd, 2000

Chemist & Druggist incorporating Relon Chemist, Pharmacy Update and Beauty Counter

Published Saturdays by United Business Media Ltd, Sovereign Way, Tonbridge, Kent TN9 1RW

On the internet at: chemdrug@dotpharmacy.com

Website: http://www.dotpharmacy.com/

Subscriptions: (Home) £137 per annum, (Overseas & Eire) \$324 per annum including postage

£2.60 per copy (postage extra)

Additional Price List £78 per annum

Circulation and subscription: United Business Media Ltd, Tower House, Sovereign Park, Lothkill Street, Market Harborough, Leics. LE16 9EF Tel: 01858 438809

Fax: 01858 434958

Reliefs on concealed subscriptions will only be provided at the publisher's discretion, unless specifically guaranteed within the terms of subscription offer

The editorial photos used are courtesy of the suppliers whose products they feature

United Business Media



Pharmacists on Tyneside write 'prescriptions' for OTC remedies

Pharmacists in the North East of England are helping to reduce GPs' workloads by writing 'self-care' prescriptions for over-the-counter medicines under a scheme starting this week.

Patients requesting an appointment at one of the three participating GP surgeries are offered a leaflet containing self-care advice and two tokens which may be exchanged for an OTC remedy recommended by the pharmacist.

The ailments covered by the scheme include cough, colds, flu, earache and stomach upsets.

The 13 pharmacies participating in the scheme receive a £250 honorarium and are reimbursed for the cost of the medicines. They also receive a £1.50 transaction fee per voucher.

"This scheme fits nicely with the NHS and Pharmacy plans in that it offers choice to the patient and enhances the role of the community pharmacist," said Dr Ian Spencer, project manager and head of primary care development at Newcastle & North Tyneside Health Authority.

The scheme, which is scheduled to last four months, is funded by the Tyne & Wear Health Action Zone and the Proprietary Association of Great Britain.

dotPharmacy

The Directory Channel goes live on dotPharmacy

There is a whole lot more useful stuff for you to look into on dotPharmacy this week. The Directory Channel lists over 10,000 pharmaceutical companies and organisations. You can use a dedicated search engine to look for products or services, or to hunt through 3,300 manufacturers and wholesalers, over 600 hospitals, 5,000 multiple pharmacy outlets, LPDs, pharmacy organisations, health authorities, special interest groups, and health charities. If you need a pharmacy contact, it's the place to look first. Visit C&D's web site at www.dotpharmacy.com and see what you've been missing.

Scottish Minister praises pharmacy input into NHS Plan

The Scottish Health Minister, Susan Deacon, has told pharmacists they will have a valuable input into the NHS Plan for Scotland, due to be published on December 14.

Representatives of Scottish pharmacy organisations met the Minister recently to discuss the profession's future role, which will be incorporated in the overall Scottish plan rather than published as a separate strategy.

Ms Deacon wrote to the Royal Pharmaceutical Society in Scotland after the meeting saying she shared pharmacists' enthusiasm for developing their role. She was "delighted" with the profession's commitment to ensuring the success of the modernisation programme.

"I and my colleagues very much look forward to working together with you and your colleagues in order to make this a reality," she said in her letter.

"In your submission, you set out a number of highly practical suggestions on many issues that are central to the improvement of health and health services in Scotland; your clear and well-considered submission will play a valuable part in the preparation of the Scottish Health Plan.

"I am greatly impressed by the energy and enthusiasm of those such as yourselves who have taken the time from extremely busy schedules to contribute their ideas."

Pharmacy organisations submitted

an eight-point plan, together with case studies illustrating 'patient journeys' though the NHS that could be improved by pharmacist involvement. Suggestions were:

- Patients stabilised on medication for chronic conditions should be able to have their repeat medication direct from their community pharmacist through a shared care package agreed between the patient, the GP and the pharmacist.
- Patients on long-term medication should have the opportunity for a medication review by the pharmacist, in agreement with the GP. This could be incorporated into pharmacists' NHS contract.
- Community pharmacists should be able to treat minor ailments on the NHS.
- Community pharmacies should be promoted as walk-in centres.
- Community pharmacists should be able to monitor patients on medicines requiring careful monitoring, such as anticoagulants.
- Greater involvement by hospital pharmacists in admission and discharge procedures would improve efficiency.
- Pharmacists should have a greater role in the management and implementation of LHCC strategies.
- The NHS Plan should explore models of remuneration for new pharmacy services, with the emphasis on patient care.



Susan Deacon

Three case studies show how the above proposals could help an elderly woman taking seven medicines for heart disease and osteo-arthritis, a young schizophrenic with difficulty taking his medicines, and a 50-year-old smoker with hypertension.

The chairs of the Scottish pharmacy bodies were to meet this week to discuss the next steps. Other organisations involved, besides the RPSiS, were the Scottish Pharmaceutical General Council, the Scottish Pharmaceutical Federation and the Association of Scottish Trust Chief Pharmacists.

Clotrimazole going GSL for prevention of athlete's foot

The Medicines Control Agency is proposing that clotrimazole 1 per cent powder be added to the General Sales List for the prevention of athlete's foot. It already has a GSL licence as an adjunct in treatment of the infection.

In its consultation letter, MLX 267, the MCA also proposes to increase the maximum GSL dose of cetylpyridinium


chloride from 3mg to 5mg for liquid oral preparations.

The MLX proposes that sodium fluoride becomes GSL for use in the prevention of dental caries. The proposed maximum strength of daily use mouth rinses is 0.05 per cent and in those for other than daily use, it will be 0.2 per cent. There are no safety issues

involved because sodium fluoride is already used in strengths of up to 0.33 per cent in cosmetic preparations.

It is also proposed to add gum ammoniacum to the General Sales List.

The consultation process will end on January 12, and the MCA plans to implement the necessary legislative changes by March 2001.



Countdown's Richard Whiteley (left) opened the centre. He is pictured with Mike Bassett (right), key account executive with BHR Pharmaceuticals, which is supplying the test equipment, Eve Knight, BCPA liaison officer, and John Gregory, special services category manager

Condoms as well as free EHC

Condoms will be given away as well as Levonelle in an emergency contraception pilot in North Wales. Pharmacists are being recruited to take part in the trial, which is expected to start on February 14, 2001.

Bridgend Local Health Group is funding a project co-ordinator, community pharmacist Mrs Alex Aubrey, and will pay pharmacists £10 per intervention, plus the cost of supplies. Detailed proposals and the patient group directions are currently being drawn up.

The organisers were hoping all 12 pharmacies in the area would take part, but one has so far declined.

Women requesting emergency contraception will be counselled and either given Levonelle or referred to a GP or family planning clinic. All will be offered a free packet of condoms.

Derby EHC pilot extended

Derby's emergency contraception pilot has been extended from seven pharmacies to 17.

The scheme is funded by the primary care groups and run by Southern Derbyshire Health Authority. Pharmacists supply free EHC under patient group directions and receive the cost of the medicine, a £50 annual retainer, and a consultation fee of £10, whether or not they issue Levonelle-2.

Pharmaceutical adviser Rebekah Cooke told C&D that the scheme could be extended to more pharmacies but future plans depended on Levonelle's legal status.

NPA extends its internet offering

The National Pharmaceutical Association is extending its internet service with the addition of the web-enabled BNF and automatic access to the PSNC web site.

WeBNF, which is updated twice yearly in March and September, will be available free to NPA net users. Members in England and Wales will also have automatic access to PSNCnet direct from the NPA's site without having to install separate software onto their computers.

In a further development, NPA net users will be given the opportunity of a free 30-day trial and a reduced subscription to Martindale on-line early in the new year.

NPA members in England and Wales who have not yet registered on NPA net will be sent a CD-rom this month that will enable them to log on (alternatively call the helpline on 020 8357 5757 and ask for a CD-rom to be sent immediately).

CPPE and BBC put pharmacists in the Learning Zone

Early birds can see the fruits of a collaborative venture between the BBC and the Manchester-based Centre for Pharmacy Postgraduate Education on BBC 2 on December 12, at 5.30am - or they can set their videos.

The programme, entitled 'Patients and Pharmacists Working Together', is aimed specifically at pharmacists. Inspired by the Government's 'Expert Patient' initiative, it looks at the benefits pharmacists can gain from listening to patients, who often have a wide knowledge of their condition.

Rob Swallow, the CPPE's assistant director, educational development, and the driving force behind the project, explains: "We wanted to alert pharmacists to the need to incorporate patients' own knowledge and expertise with their medicines into routine professional practice."

The programme is aimed particularly at pharmacists when dealing with patients on long-term prescribed medication. It has been shot using real patients and real pharmacists - Linda Bracewell of Baxenden Pharmacy in Accrington, and John Foreman and Tim

O'Donoghue of the Greenlight Pharmacy in Euston, London.

Mr Swallow is keen to encourage feedback from pharmacists, other health professionals and patients. There is a special number to call - 0845 601 2946 - and all responses received before 2001 will be entered in a prize draw.

The 30-minute production was funded by BBC Focus, which brings together

independent organisations to talk about their ideas and how they might fit into the Learning Zone, the network's early morning educational slot.

The programme is produced by Bristol-based Hummingbird Films, which won a tender based on a brief written by Mr Swallow. He says this might be a springboard for further educational TV programmes. There is potential for links with the Open University.



Linda Bracewell, CPPE tutor and pharmacist at Baxenden Pharmacy, Accrington. The production team spent over four hours filming in the pharmacy

Lords' inquiry backs stricter controls on herbal products

More rigorous controls on herbal medicine and other complementary therapies are advocated in a report published this week.

The House of Lords Science and Technology Committee is concerned about the safety implications of an unregulated herbal sector.

"We urge that all legislative avenues be explored to ensure better control ... in the interests of the public health," the Select Committee says in its report on 'Complementary and Alternative Medicine', based on a 15-month inquiry.

The Committee acknowledges that consumers often have no way of knowing whether or not a herbal or natural product is licensed.

"We recommend that the Medicines Control Agency find a mechanism that would allow members of the public to identify health products that had met the stringent requirements of licensing and to differentiate them from unregulated competitors. This should be accompanied by strong enforcement of the law in regard to products that might additionally confuse the customer with claims and labelling that resemble those permitted by marketing authorisations."

The Committee supports moves towards a European Directive that would allow licensing of herbal medi-

cines with evidence of traditional use rather than efficacy, providing they met standards of quality and safety (C&D, November 11, p5).

Any new regulatory system should respect the diversity of products used by herbal practitioners and allow for simplified registration of their stocks, the report says. In its evidence to the inquiry, the European Herbal Practitioners Association warned that too rigorous licensing of dispensing supplies could restrict practice to untenable levels.

The Committee's other recommendations include:

- The interests of the public will be best served by improved regulatory structures for many professions, with statutory regulation in some cases. Acupuncture and herbal medicine are at a stage where patients would benefit from practitioners being regulated under the Health Act 1999. Such regulation might also be appropriate, eventually, for non-medical homoeopaths.

- Only those complementary and alternative (CAM) therapies that are statutorily regulated, or have a powerful mechanism of voluntary self-regulation, should be made available through the NHS.

- Healthcare professions' regulatory bodies should develop clear guidelines on competency and training for their

members taking part in CAM.

- Provision of CAM on the NHS should continue to be through referral by GPs or their equivalent in secondary or tertiary care.

- CAM therapies should attempt to build up an evidence base with the same rigour as required for conventional medicine.

- Practitioners making specific claims for their ability to treat specific conditions should have evidence above and beyond the placebo effect.

- There is a clear need for more effective guidance to the public on what does or does not work and what treatments are safe. Because there is no central information provision, the media and other unregulated sources have an undue influence. The obvious place to turn for balanced information is the NHS, including NHS Direct.

- The NHS R&D directorate and the Medical Research Council should, with dedicated funding, develop a few centres of excellence for research on appropriate disciplines. Companies producing products used in CAM should invest more heavily in research and development.

The report (HL Paper 123) is published by the Stationery Office (£15.50), while the supporting evidence is in HL Paper 118 (£33.50) and HL paper 48 (£22.40).

JHCI code on health claims launched

A Code of Practice for health claims on foods is to be launched next week.

The code has been developed by the Joint Health Claims Initiative, established in June 1997 as a joint venture between consumer organisations, enforcement authorities and industry bodies. The aim is to prevent the use of exaggerated, misleading and prohibited health claims.

The code applies to manufacturers, retailers and others involved in the supply, promotion or labelling of foods, drinks and supplements, when making claims to the general public that the product carries a specific health benefit. It aims to clarify the difference between health claims and medicinal claims, which are prohibited for foods. A medicinal claim is defined as a health claim that states or implies a food can treat, prevent or cure human disease.

Although voluntary, the code aims to clarify and augment existing legislation and to complement existing codes and guidelines. The code is managed by an administration body, which will provide pre-market advice to companies wishing to make health claims.

All health claims must be capable of substantiation. Companies must be able to show that the food contributes a significant physiological benefit when consumed as part of a normal diet, and that the claimed effect can be achieved by consuming a reasonable amount of the food on a regular basis. The effect must be maintained over a reasonable time, unless the claim is for a short-term benefit as with folic acid in pregnancy. Companies must also state how the effect is brought about, although the exact biological mechanism need not be fully understood.

Other points include:

- Any reference to a specific disease or to disease in general terms should be avoided as it is likely to imply a medicinal benefit.
- It is acceptable to refer to the maintenance of good health in general or of a specific part of the body.
- A health claim must not encourage excessive consumption of any food or disapprove good dietary practice.
- Claims of synergistic benefit are acceptable, for example, the use of vitamin C to improve bio-availability of iron.

A section on borderline products gives examples of words and phrases that might imply prevention, treatment and cure of disease.

Further information on the code, which has the backing of the Proprietary Association of Great Britain, is available from JHCI's executive secretary, Melanie Ruffell, on 01372 822378.

APPG backs hospital pharmacy medicines management

Parliament's All Party Pharmacy Group has written to health ministers highlighting how hospital pharmacists can ensure better use of medicines.

The report recommends that practices developed at St Thomas's Hospital pharmacy department in London should be implemented nationally. The group visited the pharmacy last month and was impressed by a scheme in which patients admitted to hospital continued taking medicines already prescribed, where appropriate, saving around £100,000 a year (C&D, November 11, p6).

The MPs say that, generally, when

patients are admitted to hospital they bring with them an inexact medication history, their medication is discarded in favour of a new regime, and they receive little information on medicines. Pharmacists, despite their expertise in this area, spend little time with patients.

"This strikes us as wasteful, inefficient and unlikely to lead to optimal patient care," the report says.

St Thomas's has made significant progress in using pharmacists on ward rounds and the Government should offer explicit support for such initiatives, the report adds. Pharmacists at the hospital have also been providing

anticoagulant therapy in outpatient clinics and GP practices, making around 300 patient visits a week. Similar practices could be developed for HIV patients, cardiac rehabilitation, oncology and paediatrics.

"The principle of hospital-based pharmacists using their skills in the community, in concert with GPs and community pharmacists, is attractive."

The group sees clear merits in St Thomas's competence-based model of pharmacy practice. Pharmacists are categorised according to experience - as junior, mid-grade and practitioner - so that their skills are used to best effect.

Fulfil CE obligation by 'skilling up' for new services, urges Glover

It is time to 'skill up' to deliver new services to patients, now that the Government has said it is going to make better use of pharmacists' skills, says the Royal Pharmaceutical Society president, Christine Glover.

Pharmacists can offer many new services with only minor extra training, but it means they will need well-trained staff supporting them, to free them from the dispensary, said the president.

"At the moment the Code of Conduct requires you to undertake 30 hours' continuing education. In the near future you will have a mandatory requirement to fulfil this obligation," she told 150 pharmacists and their guests at The Oshwal Pharmacists 20th annual ball. "Linking this with developing services is a productive way to move you, your business and the profession forward."

Doctors, and shortly, nurses are required to revalidate to stay on their

registers. "Make no mistake, pharmacists will have to as well," she said.

Pharmacists have to persuade the sceptics of the value of medicines management, she said. Poor drug management is costing the nation as much as diabetes or asthma. Some 30 per cent of elderly admissions to acute services are the result of poor drug management.

"We will, in a couple of years time, be managing repeat medication. That means 70 per cent of prescriptions will be under your control. The opportunity to manage some of these will be there. It is a short step from managing to reviewing the medication," said Mrs Glover.

With the Government looking at e-commerce, nurse-prescribing and primary care centres with their own pharmacies, "we have to have a change in our thinking about moving towards services and being less dependent on supply," she added.

PSNC briefs LPCs on pharmacy plan

The Pharmaceutical Services Negotiating Committee this week highlighted the areas of the Government's pharmacy plan that LPCs will need to consider.

Over 200 LPC representatives gathered in Birmingham for the PSNC's national conference on the NHS pharmacy programme. Issues on which they were briefed included:

- NHS Direct - LPCs need to consider how they will co-ordinate participating contractors and provide advice to contractors on areas such as IT, protocols and redesign of premises.
- One Stop Centres - LPCs will need to adopt a consortium approach when considering a pharmacy opening in a centre; this may reduce the impact on surrounding pharmacies.
- Out of Hours services - LPCs need to review current arrangements and present convincing new proposals to the health authority; they should also consider threats posed by doctor dispensing.
- Repeat Dispensing - the PSNC is asking LPCs to support its national case for 28 day supply and not to encourage local schemes.
- Medicines Management - all LPCs should be preparing bids for PCTs to consider.
- Local Pharmaceutical Service contracts - LPCs must stress the advantages of community pharmacies as service providers. LPS contracts will require new legislation so discussions should not be rushed.
- A new national contract - when the details are known, LPCs will be responsible for promptly informing contractors what will be expected of them.
- Control of Entry - LPCs should co-operate with the development of one-stop centres, in order to minimise the change to 'control of entry' rules.



An in-house raffle on the night raised £250 for the Society's Benevolent Fund and £500 for the Commonwealth Pharmaceutical Association's Pharmaid scheme. RPSGB president Christine Glover receives the donations from Mrs Kalpana Shah (right), watched by master of ceremonies, pharmacist Kiran Shah

The murky politics of smoking

Having developed a keen interest in smoking, following a training event last year, I was intrigued to see the billboard advertisements currently appearing around Northern Ireland.

At first I thought the posters were advertising the dangers of smoking. How wrong could I be? These government posters are designed to stop cigarette smuggling because it depletes the coffers of much-needed tax revenue. Shock horror, 20 per cent of cigarettes are smuggled, which means that the Exchequer is losing £2 billion per year in the UK on this fraud alone.

It's strange to see the government supporting smoking so long as it does not lose money. Labour made much noise at the last election on a pledge to ban cigarette advertising, only to do a rapid U turn later!

The politics of tobacco have never been clean, proper or above board because of the huge money involved. In addition to the £10 billion a year in

"About half of all smokers die of their habit, a quarter of them before the age of sixty"

indirect taxation, there are employment considerations. Locally, Ballymena, with its Gallaghers' factory, is an example.

About half of all smokers die from their habit, a quarter of them before the age of 60. It is fine to talk about freedom of choice, but few smokers want to smoke. They can't beat an addiction more powerful than heroin.

I truly felt that this government was committed to smoking cessation and implementing policy to effect change. Perhaps the experience with the fuel-tax lobby has ensured that government must remain certain of its tax revenue. Whether tax comes from activities that improve people's lives or kill them is not really relevant. The voter will not pay income tax of more than 23p in the pound, yet will demand all the securities expected in a modern society. It's not surprising that government has to deceive. I might feel better if the tax collected from cigarettes went directly to healthcare. Some chance.

Written by a practising Northern Ireland pharmacist

Xrayser

Topical Reflections

PGDs go national much sooner than expected

The usefulness of patient group directions could be tested a lot more quickly than I had ever envisaged, and without the facility to test the efficiency of their delivery.

Suddenly, from being *personae non grata* under the NHS, both pharmacists and Relenza have been accepted as helpful for high-risk flu victims.

Since the medication must be administered within 48 hours of the symptoms first appearing, the Department of Health has strongly suggested that PGDs for pharmacists and nurses are the most convenient and efficient way of patients getting Relenza.

However, despite the urgency of setting up the PGD, I am concerned that the consequences for community pharmacists are also addressed. This is not a service that can be delivered using present dispensing fees as a template for payment.


Each PGD completed must command an appropriate fee, and this must reflect both the time required and the professional role of the pharmacist. If delivery is required this must be at the discretion of the pharmacist, but the expense incurred must be reimbursed.

Finally pharmacists cannot be left with unused stock at the end of the season. If supply is by the normal route, then Glaxo Wellcome must put into place a mechanism for returning any unused stock for full credit.

I am excited about this development because, despite the time pressure of having a system in place across the busy Christmas period, community pharmacists at last have the opportunity to demonstrate their ability to co-operate and to deliver a much-needed service.

The Department of Health says the PGD route of supply is not mandatory, but there is a strong recommendation that community pharmacists should be involved.

It would be politically naïve for any primary care group to restrict supply to nurses and exclude community pharmacists from the system.



Muddying the waters

I am amazed how the cheapest of drugs can suddenly become like gold dust and even, as in the case of Isoniazid, now only supplied on a named patient basis.

However the original economics of manufacture - assuming the same volume of sales - should still apply, so when I received a letter of explanation from Penn Pharmaceuticals about the apparent confusion over the cost and reimbursement of Isoniazid, I was relieved.

But having read the letter I am now even more perplexed and, as a taxpayer as well as a contractor pharmacist, doubly concerned. I was reassured to learn that in future my invoice from Penn will be broken down into cost plus distribution on-cost, plus carriage and, despite Isoniazid being a category C drug in the Tariff, I will be fully reimbursed. What I am not told is how much I have been previously reimbursed when this clarification was not to hand! That is my potential loss but what about the taxpayer?

Unspecified regulatory problems have meant that the sole product licence holder, Norton Pharmaceuticals, has had to temporarily restrict supplies on named patient basis. Since the

company does not possess the administrative structure to deal with these transactions, it has by competitive tender appointed Penn Pharmaceuticals as its agent.

According to the letter, I will be reimbursed a cost of £5.77 per 28 tablets of 100mg (which is a tenfold increase in cost compared with 1999) and, to add insult to injury, with an additional charge of £8.50 per 28 tablet pack, regardless of the quantity ordered, to cover the cost of administering the named patient system.

I am not a party to the detail of the tender bids but I now know that every 28 tablet pack of Isoniazid purchased, regardless of strength, is costing the NHS £14.27 whereas in 1999 it was 55p. And that is what Penn Pharmaceuticals and Norton call clarification.

Join the soapbox brigade!

Writing letters can be a bore, but sending e-mails is quicker and more fun! From this you may deduce that I am no longer a technological dinosaur.

I cannot reveal my personal e-mail address, but C&D has its own e-mail address at Chemdrug@unitedbusinessmedia.com. Just address your thoughts for the attention of Xrayser and join the soapbox brigade!

RPSGB promotes uptake of smoking cessation audit

The Royal Pharmaceutical Society is encouraging pharmacists to make use of its smoking-cessation audit tool, which is freely available via its web site (www.RPSGB.org.uk).

David Pruce, audit development fellow at the Society, says: "The tool assists pharmacists analyse the help they give to people wanting to give up smoking and to measure the effectiveness of their interventions."

The tool was piloted in 25 pharmacies in the Bromley area. It was found that most of the participating pharmacists thought they had less impact in smoking cessation than did the patients involved. "The underlying message is that pharmacists should be confident when giving proactive advice and offering follow-up support," says Mr Pruce.

Longer term, the tool could be used as a standard against which pharmacists are paid, suggested Miriam Armstrong of the Pharmacy Healthcare Scheme. It aims to promote good practice, but may become a benchmark for pharmacy smoking cessation services, she said.

The Society hopes that all pharmacists taking part in No Smoking Day will use its audit tool to evaluate their services during the following month. The resulting data can then be fed back to Mr Pruce, who will analyse the results and present the findings at a later date.

Other planned smoking-cessation activities that will involve pharmacists include a nationwide series of seminars, distribution of health promotion material, and a television advertising campaign.

The first in a series of smoking-cessation seminars promoting the pharmacist's role, which was held in Whitechapel, attracted more than 200 representatives from all branches of the Health Service. There are eight of these seminars planned at venues around the country. The next one will be held in the North West on January 16. Details of others will follow.

A television advertising campaign that advises smokers to choose between their pharmacist and a funeral director will resume in December and run until No Smoking Day. The Department of Health campaign will be shown on terrestrial television across all regions.

The Department of Health will be distributing its new smoking-cessation campaign materials through pharmacies in England in early December. Materials include helpline cards, an information sheet and an A3 poster.



Pharmacists targeted in Welsh quit smoking push

Welsh pharmacists are being targeted by the Health Promotion Division in Wales as part of its stop-smoking campaign, to be launched on January 3.

The Quit & Win 'recruiters challenge' hopes to encourage pharmacists, along with GPs and nurses, to enrol smokers in the competition.

Teams that recruit at least five smokers to the campaign will be entered into a draw with the chance of winning a long weekend for six in a luxury resort in Pembrokeshire.

The Wales Quit & Win Challenge 2001 will run until April next year and will give smokers who want to quit an extra incentive in the form of prizes. These include a Daihatsu Cuore Plus car and short European breaks.

More than 3,000 Quit & Win information packs are being distributed to health professionals in early December. To request a pack call 0800 169 0169.

● Vantage pharmacy staff are currently being offered training on smoking cessation. The programme, produced in conjunction with product manufacturers, covers product knowledge and the provision of advice.

AAH marketing director Ian Bray says the training is being made available now because in the run-up to the New Year many people consider giving up smoking. AAH's research suggests that of those still currently smoking, 70 per cent will have tried to stop, and half of these will have made at least three attempts to quit.

Lottery money supports smoking cessation initiative

Pharmacists in Tooting, South London, are taking part in a Healthy Living Initiative supported by £900,100 from the New Opportunities Fund, a National Lottery distributor.

A smoking-cessation programme is one of six projects aimed particularly at ethnic minorities. Pharmacists will supply five weeks' free nicotine replacement therapy and see clients every week for a month, spending two hours overall with each one.

About ten pharmacists expressed interest initially, but a more flexible approach is being investigated to attract those who are unable to spend as much time with each client.

Inderjit Patel, one of the pharmacists helping to organise the scheme, said that structured counselling gives the best results, but there is evidence that a telephone call at the right time can help, as can encouraging a group of 'quitters' to support each other. The fee is still under discussion, but should be at least £20 a client.

Help will also be available to people using oral tobacco, and pharmacists will be on the look-out for patients with symptoms of chronic obstructive pulmonary disease who

could be potential targets for smoking cessation.

Dr Tom Coffey, who chairs Tooting Primary Care Group, told *C&D*: "We hope that in two years' time virtually all smoking cessation will be run by pharmacists."

Other programmes in the healthy living initiative include heart disease, in which pharmacists could be involved in medicines management.

The Heartbeat Award scheme will highlight the importance of reducing salt and fat intake by rewarding local restaurants for healthy menus. Organised walks in the summer and swimming sessions will encourage people to take more exercise.

The Tooting award comes from the New Opportunities Fund's £300m healthy living centres programme.

● Tooting PCG is planning a repeat prescribing project in which pharmacists will inform GPs of prescription anomalies such as inequivalence in the amount of drugs prescribed, medicines that the patient has stopped taking and dosages that are out of line.

Pharmacists will be paid £1 per intervention, in an attempt to cut wastage.

Nicorette Patch

Abbreviated Prescribing Information. Nicorette Patch

Presentation: Transdermal delivery system available in 3 sizes (30, 20 and 10cm²) releasing 15mg, 10mg and 5mg of nicotine respectively over 16 hours.

Indications: Nicotine dependence and symptom relief in smoking cessation.

Dosage & Administration: Nicorette patches should not be used concurrently with other nicotine products and patients must stop smoking completely when starting the treatment. The recommended treatment programme should occupy 3 months. One Nicorette patch should be applied to a dry, non-hairy area of the skin on the hip, upper arm or chest, in the morning and removed at bedtime.

Application should be limited to 16 hours within any 24 hour period. Patients are recommended to commence with one 15 mg patch daily for the first 8 weeks. Patients who have remained abstinent should then be supported through a weaning period, consisting of one 10mg patch daily for 2 weeks followed by one 5mg patch daily for a further two weeks. Patients should be reviewed at 3 months and if abstinence has not been achieved, further courses of treatment may be recommended if it is considered that the patient would benefit.

Precautions: Peptic ulcer, angina pectoris, recent myocardial infarction, serious cardiac arrhythmias, systemic hypertension, peripheral vascular disease, diabetes mellitus, hyperthyroidism, phaeochromocytoma, recent cerebrovascular accident, chronic generalised dermatological disorders.

Contra-indications: Pregnancy & Lactation. Non-smokers, children under 18 years, known hypersensitivity to nicotine or component of patch.

Special Warnings: Rarely dependence. Erythema may occur. If severe or persistent discontinue treatment.

Adverse Effects: Application site reactions (e.g. erythema and itching), headache, nausea, dizziness, palpitations, dyspepsia and myalgia.

Pharmaceutical Precautions: Store below 30°C.

Legal Category: P.

Package Quantities & Cost (all trade prices correct at time of printing):


Cartons containing Nicorette patches in single sachets in the following quantities: Nicorette Patch 15mg (PL0022/0105) – packs of 7 (£9.07). Nicorette Patch 10mg (PL0022/0104) – packs of 7 (£8.36). Nicorette Patch 5mg (PL0022/0103) – packs of 7 (£7.20)

PL Holder: Pharmacia Laboratories Ltd trading as Pharmacia, Davy Avenue, Milton Keynes, MK5 8PH. Tel. 01908 661101.

Date of preparation: July 2000.

REFERENCES: 1. Fagerstrom KO, Sachs DPL. Medical management of tobacco dependence: a critical review of nicotine skin patches. *Curr Pulmonology* 1995; 16: 223-38.

NICORETTE



NICOTINE CRAVING BY DAY.

NICOTINE CRAVING BY NIGHT.



Smokers don't smoke while they sleep, so why provide them with nicotine replacement therapy all night? Nicorette 16 hour Patch closely mimics a regular smoker's nicotine intake during normal waking hours. Because it keeps cravings under control all day, but leaves smokers nicotine-free at night, there's less chance of sleep disturbance! So next time regular smokers need continuous craving relief, help them have a restful night too, with Nicorette 16 hour Patch.

NICORETTE

contains nicotine

16 hour Patch

CRAVING FREE DAYS · NICOTINE FREE NIGHTS

Medical matters



IN BRIEF

Drug Tariff matters

The DoH and the National Assembly of Wales have agreed to allow NCSO endorsements for clomiphene 50mg tablets for December scripts. Vitamin B Compound tablets are deleted from Part VIII of the Tariff with effect from December prescriptions. The PPA says that glibenclamide 2.5mg tablets have been deleted in error from the December Tariff. The item continues to be reimbursed under Part VIII, Category A at a price of 96p per 28 calendar pack and will be reinstated in January 2001.

Fresenius launches Calshake

Fresenius Kabi has launched Calshake powder, a high-energy powdered supplement that is available on prescription (ACBS). It is available in banana, chocolate, strawberry and vanilla flavours. A box of seven sachets costs £12.36. Fresenius Kabi. Tel: 01925 898000.

'Understanding stroke'

Family Doctor Publications has added a new title to its series. 'Understanding stroke' is written by Dr Richard Lindley, a consultant physician and geriatrician. It retails at £3.50 (ISBN 1-898205-60-4).

Family Doctor Publications.

Tel: 01295 276627.

Cipramil drops return

Following a recall, Cipramil drops 40mg/ml are once more available. Lundbeck. Tel: 01908 649966.

Skin disease a major problem for the elderly

Up to 70 per cent of elderly people in the UK are suffering from skin diseases, many of which are preventable, according to a report.

The Associate Parliamentary Group on Skin's report claims that poor access to treatment and information remains a major cause of health inequality among people over 60 years old.

There is considerable potential for more skin disease in the elderly to be treated in primary care, recommends the report. It also recommends extending the use of prescribing to link primary and secondary care.

John Walsall South and chairman of the group, Bruce George, said: "We hope the report will be given serious consideration during the preparation of the NHS for older people."

Survey finds that one in ten children are taking drugs

Over 10 per cent of 11-15 year-olds have used drugs in the past year, according to a survey by the government body, National Statistics.

Cannabis was the most popular drug, with 11 per cent using it in the past year. Less than 0.5 per cent had used opiates, and 1 per cent had used crack or cocaine.

The survey shows a slow but steady increase in the numbers of children using drugs. In a 1998 survey, only 7 per cent of this age group admitted using drugs during the previous month. Although not statistically significant, the results show increases among both boys and girls, particularly among those aged 14 and 15.

Drug use appears to be related to educational factors and anti-social

behaviour. Over a quarter of children who said they did not do well at school had used drugs during the past year. And children who had used drugs recently were five times more likely to have been in trouble with the police or to have been excluded from school.

The survey of over 9,000 secondary school children from about 340 schools in England found that the number of regular smokers fell from 11 per cent in 1998 to 9 per cent in 1999. Drug use is strongly related to smoking experience, with 56 per cent of regular smokers using drugs in the last month.

There was no change in drinking levels between 1998 and 1999 - 21 per cent of children had drunk alcohol during the previous week.

PPA products must show more prominent warnings

The Committee on Safety of Medicines has recommended that the warnings on preparations with phenylpropanolamine in them should be more prominent.

The Medicines Control Agency has been advised to work closely with manufacturers to improve existing information on the packs and patient information leaflets of PPA-containing products. This is the only recommendation from a CSM meeting last

Thursday that reached the same conclusions on safety issues as at a meeting earlier this month (C&D November 18 p8).

A DoH spokesman said: "PPA-containing products should not be used by certain groups, such as those with high blood pressure or heart disease. These warnings and contraindications are stated on the packaging and patient information leaflets."

AF therapies have equal effect

Controlling heart-rate and heart rhythm are equally effective for controlling the symptoms of atrial fibrillation (AF), according to a study in *The Lancet*.

The Pharmacological Intervention in Atrial Fibrillation Trial (PIAF) compared AF patients' symptoms after they had been treated with either diltiazem or amiodarone. Over 250 patients were randomised to either heart rate control using diltiazem (group A) or heart rhythm control using amiodarone (group B).

The end point was assessed by changes in the three most commonly

reported AF symptoms - palpitations, dyspnoea and dizziness. Over the year-long observation period, a similar proportion of patients from both groups reported improved symptoms.

Hospital admissions were higher in group B (87 out of 127 patients) than group A (30 out of 125). Adverse effects more frequently led to a change in therapy in group B (25 per cent) than group A (17 per cent).

The study's authors concluded that their findings may have important implications for the care of AF patients who are treated mainly for symptomatic reasons.

Ulcer drugs now top BNF section by cost for GPs

Ulcer healing drugs are now the top BNF section by cost for GPs in England, accounting for 8 per cent of total prescribing costs.

The latest set of PACT data from the Prescription Pricing Authority shows that prescribing of these drugs has increased by 36 per cent over the last five years. This equates to increased spending of 14 per cent.

For the quarter to June 1995, almost two-thirds of prescriptions were for H2 receptor antagonists (H2RAs) and one-third for proton pump inhibitors (PPIs). This pattern is now reversed, with PPIs accounting for almost three-quarters of spending in this category for the quarter to June 2000.

Omeprazole is the most frequently prescribed PPI, accounting for 49 per cent of items. It is followed by lansoprazole, which accounts for 41 per cent. Ranitidine accounts for 61 per cent of H2RA prescription items, compared to 26 per cent for cimetidine.

Prescribing of antacids and other related dyspepsia drugs has fallen by 10 per cent over the last five years, while prescribing of alginic acid preparations has hardly changed. Alginic acid preparations are the most commonly prescribed antacids, and spending on them has increased 16 per cent over five years.

About 10 per cent of the population ask their GP for advice on dyspepsia each year, and 10 per cent of these are referred to a specialist. The main causes of dyspepsia are:

- gastro-oesophageal reflux disease - 15-25 per cent
- gastric and duodenal ulcers - 15-25 per cent
- stomach cancer - 2 per cent
- non-ulcer dyspepsia - up to 60 per cent.

Leo launches tablets

Leo has launched Centyl K tablets, containing bendrofluazide 2.5mg and potassium chloride 573mg. They are licensed for treatment of oedema of cardiac, hepatic or renal origin, blood pressure control in mild to moderate hypertension, and prophylaxis against recurrent renal calcium stones. Basic NHS price is £5.44 for a pack of 56.

Leo Pharmaceuticals Ltd.

Tel: 01844 347333.

NURSES GET 20% EXTRA FUNDING

NURSES HAVE been awarded



Record £2.4million advertising budget for 2000.

It's our highest advertising spend ever. But we're sure you'll agree they deserve it. After all, Night Nurse and Day Nurse is the No. 1 pharmacy only cold and flu brand.* And totally dedicated to maximising your profits this winter. With new 'embossed' packaging for increased standout, it's time to stock up now. And let these 'Nurses' take care of your customers and your business.

*Source: IRI. Night Nurse and Day Nurse are registered trademarks of SmithKline Beecham

DEDICATED TO PHARMACIES. DEDICATED TO COLDS & FLU.



Counterpoints



Acidex increases its liquid assets

Pinewood Healthcare is launching a liquid product to provide relief from the pain of heartburn and indigestion.


Acidex Compound Alginate Oral Suspension Heartburn and Indigestion Liquid is an aniseed-flavoured suspension.

The active ingredients are sodium bicarbonate, sodium alginate and calcium carbonate. The formulation is sugar and gluten free.

The product is suitable for adults and children over six years. It is also indicated for heartburn in pregnancy and may be used during lactation.

Retail price is £4.89.

Pinewood Healthcare.
Tel: 00 353 52 36253.




Cough, cold & flu FORECAST

Information updated weekly by SDI

SPONSORED BY



United Kingdom	Status level	Number of weeks on status	Season 2000/2001 projected population affected by respiratory illness	2000/2001 vs 1999/2000 cumulative season to date % difference
BIRMINGHAM	Advisory	7 weeks	162,089	12.23%
BRISTOL	Advisory	7 weeks	34,881	40.04%
GLASGOW	Normal	1 week	45,884	-35.81%
LEEDS	Advisory	8 weeks	113,029	18.83%
LONDON	Pre-Alert	1 week	714,818	-4.84%
MANCHESTER	Advisory	7 week	249,756	18.60%
NEWCASTLE	Pre-Alert	1 week	21,128	9.72%
NORWICH	Pre-Alert	1 week	11,910	6.55%



Night Nurse takes to the airwaves

SmithKline Beecham is supporting its Night Nurse pharmacy-only cold and flu brand with a £2.4 million TV and radio advertising campaign this winter.

Featuring a return of last year's upbeat Night Nurse commercial, the national TV campaign will run from December 4 until January 21.

This year, the same advertising

theme will be used across both TV and radio to target the brand's core market - predominantly women aged 25-44.

PoS material to support the brand includes bunting, hanging banners, cubes, dummy packs and shelf edgers.

SmithKline Beecham Consumer Healthcare.

Tel: 020 8560 5151.

Getting back on top of the world with Alka-Seltzer

Bayer is supporting Alka-Seltzer with a £1.2 million Christmas marketing campaign.

TV advertising for Alka Seltzer will be on air for the next three weeks. Featuring a comical view of the planetary system, the commercial uses animations to show a hungover Earth bumping into planets.

The Earth breathes a sigh of relief as it gets back to normal, with the strapline 'Alka-Seltzer XS, for when you're not feeling on top of the world.'

The campaign also includes PoS material to complement the TV advertising. Shelf edgers, dump bins and counter units are available.

Regional activities target students and the youth market. These include a creative postcard campaign throughout London's top bars.

Bayer is introducing National Hangover Day on New Year's Day to promote Alka-Seltzer. The company will be offering drinkers advice on how to achieve a clearer start to 2001 through coverage in magazines and newspapers.

Bayer plc.
Tel: 01635 563000.

Gladiator Wolf gives Throaties a big-screen boost

Ernest Jackson is supporting its Throaties medicated throat pastilles with a £2 million cinema advertising campaign this winter.

The 'Big softies for sore throats' campaign, which was first shown last year, shows the softer side of the notoriously aggressive Gladiator 'Wolf'.

The commercial will be screened in cinemas throughout the country during December, January and February.

The campaign is targeted at females aged 15-24 who are the heaviest users of medicated confectionery.

Ernest Jackson & Co Ltd.

Tel: 01363 772251.

Licensed 50:50 Ointment

BCM Specials is launching 50:50 Ointment (50 per cent white soft paraffin, 50 per cent liquid paraffin) as a fully-licensed 'P' product. The ointment is indicated for symptomatic relief of dry skin conditions. Retail price is £11.40 for 500g.

BCM Specials.
Tel: 0800 952 1010.

WANT TO BREATHE LIFE INTO YOUR WINTER HEALTHCARE BUSINESS?

VICKS

Support the UK's Favourite Inhalant Decongestant Brand in Pharmacy*

£2 Million winter
TV campaign

New Vicks VapoRub
TV advert to drive
consumption by
adults

Separate TV support
for Vicks Sinex



for every breath you take

All value shares Sept 99-April 00 Vicks 11.5%, Olbas 5.9%

Vicks VapoRub

Active ingredients: Levomenthol 2.75% w/w Camphor 5.00% w/w Eucalyptus oil 1.50% w/w Turpentine oil 5.00% w/w **Indications:** For the symptomatic relief of nasal catarrh and congestion, sore throat, also coughs due to colds. **Dosage and administration:** Adults: Rub VapoRub liberally onto chest, throat and back, rub in well and leave clothes loose for easy inhalation or melt two teaspoons in very hot water and inhale the vapours. Children (infants and babies over 6 months): apply lightly to the chest and back and rub in well, leaving clothes loose for easy inhalation. **Contraindications:** Use in babies under 6 months of age. **Precautions, side effects and warnings:** Patient should see doctor if symptoms persist or fever develops. Keep out of reach of children. **Product licence number:** PL 0129/5009R. **Product licence holder:** Procter & Gamble (Health & Beauty Care) Limited, Brooklands, Weybridge, Surrey KT13 0XP Legal category: GSL Price (excluding VAT): £1.89 Date of preparation: September 1999

Vicks Sinex Decongestant Nasal Spray

Active ingredients: Oxymetazoline hydrochloride 0.05% w/v **Indications:** For symptomatic relief of congestion of upper respiratory tract due to common cold, hayfever or sinusitis. **Dosage and administration:** Nasal administration. Adults and children over 6 years: 1-2 sprays per nostril every 6-8 hours unless otherwise advised by a doctor. **Contraindications:** Patients should consult their doctor prior to using product if they suffer from high blood pressure, any heart complaint, diabetes, thyroid disease, hepatic or renal disorders. **Precautions, side effects and warnings:** Patient should see doctor if they feel worse, or no feel better after 7 days, are taking other medicines, intend to become pregnant, are pregnant, are breastfeeding or if new symptoms develop. **Product licence number:** PL 0129/5011R. **Product licence holder:** Procter & Gamble (Health & Beauty Care) Limited, The Heights, Brookland, Weybridge, Surrey KT13 0XP Legal category: GSL Price (excluding VAT): £2.88 Date of preparation: September 1999

'Use your head' urges Brylcreem campaign

Sara Lee is supporting its Brylcreem men's haircare range with a national TV campaign throughout December.

The 'Use your head' commercial features Iddo, the star of BBC's new *Attachments* series. It shows Iddo going through his morning grooming routine, effortlessly styling his hair with Brylcreem before leaving - with a bag of frozen peas! The end frame of the commercial highlights Brylcreem Ultra Gel's recent award for best haircare product in *Maxim* magazine's Style Awards.

Ultra Gel, which glows under UV light, was launched in a limited edition version. UV Glow will be available in the UK in 2001.

Sara Lee UK Ltd.

Tel: 01753 523971.



SB broadens Aquafresh Flex with chunky handle

SmithKline Beecham is introducing a premium, chunky-handled toothbrush in its Aquafresh Flex range.

Aquafresh Max Active is an ergonomically-designed toothbrush with a two component rubber and plastic handle. It is available in two formats - X-Active with cross-angled bristles (lime green pack) and Concave with bristles that curve inwards (blue pack). Both feature a cleaning tip and medium textured bristles. Brushes come in four colours - orange, blue, turquoise and lilac.

The blister card packaging accentuates the S-bend flexible neck and chunky handle. Retail price is £3.49.

SmithKline Beecham Consumer Healthcare.

Tel: 020 8560 5151.



Santo's natural nipple care for nursing mums

Santo Products is launching a natural nipple care ointment for nursing mothers.

Rafael Natural Nipple Care Ointment is formulated to rapidly soothe and nourish the nipple area. The company says 30 per cent of

nursing mothers suffer from sore and cracked nipples.

The product's natural ingredients include oils of hypericum, wheat germ and extracts of chamomile and ginseng. Formulated to be a completely safe product for mother

and baby, the ointment is non-toxic and contains no preservatives. There is no need to wipe the ointment off before the next feed.

Retail price is £5.76.

Santo Products Ltd.

Tel: 020 8952 0668.

An eye opener from Optrex

Crookes Healthcare is launching a new initiative for its Optrex Fresh Eyes which is being teamed up with the Ruby & Millie cosmetics brand.

A consumer PR campaign featuring Optrex Fresh Eyes and Ruby & Millie will run until March. The campaign features photography by top fashion photographer David Woolley.

Optrex Fresh Eyes is also being supported with trade activity and promotions until January. This

includes sampling through Ruby & Millie consultants in Boots the Chemists stores throughout December.

Crookes Healthcare Ltd.
Tel: 0115 953 9922.

Arden masks will Clear the Way

Elizabeth Arden plans to launch three treatment masks in its updated skincare collection in February.

Deep Cleansing is a deep-cleansing clay-based mask for oily skin. It contains extracts of birch bark, ginseng, watercress, calendula and cucumber.

Hydrating Mask is an intensely moisturising mask for dry skin. It is formulated with shea butter, camomile plus extracts of ginkgo biloba and kiwi fruit.

Clear the Way is a refining mask for normal skin. Its ingredients include algae extract and peppermint extract.

All three masks will retail at £15.00.

Elizabeth Arden Ltd.

Tel: 020 7574 2700.

ON TV NEXT WEEK

Aquafresh: All areas except U, CTV

Askit: GTV, GMTV, C4, C5

Avent Magic Cup: C, W, CAR, Sat

Beechams: U

Beechams Cold & Flu: All areas except U, CTV

Benylin: All areas

Calpol: ITV, GMTV, Sat

E45 & Skin Confidence E45: All areas except LWT, C4, GMTV, TSW

Gaviscon Advance: All areas

Haliborange: GMTV

Lemsip: All areas except CTV

Night & Day Nurse: All areas except U, CTV

Nytol: All areas

Panadol: U

Sensodyne toothpaste: All areas

Solpadeine: U

Sudafed: All areas except GMTV

Zantac 75 + Zantac 75 Relief: GTV, STV, C, C4, C5, TSW, Sat

Zovirax: C4, C5, ITV, Sat

Pharmasite next week: Motilium 10, Anadin - Window. Motilium 10 - In-store. NHS Direct, Canesten Thrush Cream - Dispensary

Anglia, **B**order, **C**entral, **C4** Channel 4, **C5** Channel 5, **CAR** Carlton, **CTV** Channel Islands, **G**ranada, **GMTV** Breakfast Television, **GT**V Grampian, **HTV** Wales & West, **LWT** London Weekend, **M**eridian, **Sat** Satellite, **STV** Scotland (central), **TT** Tyne Tees, **U**Ulster, **W**Westcountry, **Y**Yorkshire



Pokémon vitamins for kids to chew on

Nutricia is supporting its recent launch of Sundown Pokémon multi-vitamins for children with press advertising and in-store PoS material.

The chewable children's vitamin brand, which was launched in the UK at Chemex in September, is being advertised in women's interest magazines until February.

Targeted at children aged four to 14, the range is designed to maximise on the current Pokémon craze among youngsters. Pokémon Multi, Pokémon

with Iron and Pokémon with Extra Vitamin C come in four fruit flavours and are shaped and embossed with each of the four Pokémon characters. Each pack contains 60 tablets (two month's supply) and retails at £5.99.

Merchandising material includes a 48-unit floor display, an eight-unit gravity feed counter display, posters, mobiles, pamphlets and holders.

Pokémon is the first Sundown range to be launched in the UK following Nutricia's acquisition of US

company Rexall Sundown.

Nutricia is expected to introduce other Sundown vitamin and herbal supplements in the UK next spring.

Nutricia Ltd.
Tel: 01225 711677.



Pharmacia to help smokers quit

Pharmacia & Upjohn will support its Nicorette range with a £2.7 million advertising campaign aimed at people who plan to give up smoking as a New Year's resolution.

ATV commercial focusing on Nicorette Gum will commence on Boxing Day and run throughout January.

Tube card advertising for Nicorette Gum and Nicorette Microtab will appear on London Underground trains for the last two weeks of December and the first two weeks of January.

A Pharmasite poster initiative featuring the Nicorette Patch, Nicorette Gum and the Nicorette Inhalator will run in pharmacies throughout January. PoS material to support the brand includes posters, giant packs, and counter units.

Pharmacia & Upjohn.
Tel: 01908 661101.

Pro Plus awakes the festive spirits

Roche Consumer Health is supporting its Pro Plus brand for temporary tiredness with a regional TV campaign during December.

The campaign targets late night viewers in their battle against tiredness over the festive season - known to be the most tiring period of the year.

The humorous commercial features a weary shop cashier absentmindedly scanning items through the till - including a small dog!

The advertisement ends with a short, sharp wake-up call for anyone dozing off in front of a TV screen.

It will be shown in London and the North between the hours of 11pm and 6am from December 4.

Roche Consumer Health.
Tel: 01707 366000.

SOLPADEINE

Your good advice can really help sort out those trapped by their backache. Recommend Solpadeine, and remind your customers that 90% of Solpadeine users stay loyal to it.*

Solpadeine is pharmacy-only, so every recommendation makes good professional and commercial sense.

Your recommendation makes all the difference

*Taylor Nelson Sofres Healthcare 1998. Solpadeine is a trademark.
Further information is available from: SmithKline Beecham Consumer Healthcare,
Great West Road, Brentford, Middlesex TW8 9BD. Legal Category P.



paracetamol, codeine, caffeine

As the prevalence of every day low pricing (EDLP) in supermarkets spreads, pharmacies are finding it increasingly difficult to compete on the price of toiletries and baby products.

In some cases where sales have increased in the supermarkets, it is clear that switching between store types has occurred.

However in other areas, the multiples are facing similar issues and it could be that the reduction in the value of the market has more to do with EDLP.

Kissing baby goodbye

Babycare products, and in particular nappies, have always had a strong presence in pharmacies. Yet, pharmacy sales of nappies have fallen by almost 30 per cent in the past year; customers are obviously buying them elsewhere.

Baby foods and drinks, which have struggled in pharmacies, are also seeing growth in the supermarkets.

Categories like vitamins and hair colorants, which have historically been large within pharmacies, remain prominent but are beginning to decline.

Niche pharmacy sales

While people increasingly buy toiletries with their grocery shopping, it is the niche markets that are growing in pharmacies.

Some areas are showing potential, albeit the smaller categories. Anti-tiredness is a prime example; it has been worth only £1.5m over the last year in chemists but has grown by 14 per cent.


This has been driven by the continued progress of Pro Plus. Despite having been available for

Market analyst Information Resources reports on how sales of health and beauty aids are performing in pharmacies

Supermarket sweep

Fastest growing health & beauty categories

Chemists excl BIC



over 40 years, it is only in the last few years that its use has increased significantly.

While Pro Plus is an all-purpose product, the manufacturers of Verve (Tagg NPD) have begun to produce a number of variants with a more specific target market.

Verve Female, Verve Mum To Be and Verve Defence, to aid the immune system, have all started life on shelf promisingly. But the most successful

Verve product has been the generic Verve Get Up & Go.

Grocery promotions

On the whole, oral care is another of the sectors moving the way of supermarkets. However, niche oral care products, such as dental fixatives, are retaining their market in pharmacies.

Procter & Gamble have only one brand in this market, but tellingly it is

the number one single brand. Fixodent holds an 18 per cent share of the market and has grown by 10 per cent in the last year.

Stafford Miller dominates the market with a large range of products and has a 57 per cent share of the category. Poli Grip Ultra is its best-selling variant and while this has declined slightly over the last year, the growth of Super Poli Grip and Poli Grip Flavour Free have more than made up for the shortfall.

Few growing brands

Of the top ten brands in the chemist sector, only two are growing. One is the ubiquitous Gillette Mach 3 razor, but even its strong performance has not been enough to prevent the razors and blades category from declining within pharmacies.


The other is Clearblue One Step. The Clearblue brand was first launched in 1985 and within three months had become market leader, a position it retains 15 years on.

The One Step product was launched in 1988, providing a simple, accurate test result in three minutes. Despite being one of the more expensive brands available, it is by some distance the first choice of the consumer.

Top 10 health & beauty brands in Chemists

Chemists excl BIC

■ 52 w/e 10 Oct 99
■ 52 w/e 8 Oct 00



WHEN TOO MUCH CHRISTMAS CHEER LEAVES CUSTOMERS FEELING A TAD ~~GROGGY~~





REACH FOR...

If customers feel a tad green after eating and drinking especially that little bit too much, or have that 'lead weight in their tummy' feeling, recommend Motilium 10. It's the only OTC motility product clinically proven to restore a normal stomach digestive rhythm, and it's only available from pharmacy.

So if their stomachs get them down this Christmas give them the belief they need.

Motilium 10. Gets stomachs back to work

Johnson & Johnson - MSD

CONSUMER PHARMACEUTICALS



E45 kids just get on with it

New E45 Shower Cream is a clinically proven soap substitute for the management of eczema and other dry skin conditions.

Whereas soaps make eczema worse, E45 Shower Cream is non-drying and actively rehydrates dry skin.

E45 Shower Cream is also cosmetically acceptable and easy to use.

Which is why kids with eczema get on so well with E45, and why you can recommend New E45 Shower Cream with confidence.



At ease with
eczema

NEW



PHARMACYupdate

The wet ones

The water-soluble vitamins, B and C, are vital for normal physiological function.

Nutritionist Esther Mills explains how they work and how deficient patients are affected



Water-soluble vitamins are vital for correct functioning of every single body cell and we rely on a constant supply from our diet to keep us healthy. The most famous of them all, vitamin C, was the first used to alleviate deficiency syndromes (in the case of vitamin C, 'curing' scurvy in 1747) and this paved the way for years of research into these fascinating compounds.

Today, nutritional science has established which vitamins can be classed as water soluble, their specific roles in the body, dietary deficiencies, contra-indications with medication and safe supplementary intakes.



Definition

Historically, much of the early work on vitamins began with identifying the chemical and physical characteristics of each particular nutrient. The discovery that factors in food could 'cure' diseases such as scurvy (vitamin C), beriberi (vitamin B1) and pellagra (vitamin B3) sparked scientific interest in isolating the compounds that gave health benefits.

This took many years of research into what were then called 'protective foods'. Vitamin C was first discovered in the late 18th century. But it was not until 1928 that 'water soluble C' was

isolated and renamed ascorbic acid because of its chemical properties. Today, the classification 'water soluble vitamins' includes all B group vitamins and vitamin C.

Nowadays, biochemical research is determining the precise mechanisms of action of these nutrients. This is summarised in table 1.

Deficiencies

Improved nutrition, along with higher standards of hygiene and better standards of living, has brought great improvements in health since the end of the 18th century. Today, vitamin deficiency



Water-soluble vitamins

Their sources and their uses



Constipation

Everything that pharmacists should know about this common condition

VI

Paediatric medicines

Recommendations on the use of unlicensed medicines in children

XII



THE COLLEGE OF PHARMACY PRACTICE

THIS COURSE (MODULE 1184), IN ASSOCIATION WITH MULTIPLE CHOICE QUESTIONS BEING PUBLISHED IN C&D JANUARY 13, PROVIDES ONE HOUR'S CONTINUING EDUCATION

OBJECTIVES

- To recognise dietary sources of water-soluble vitamins
- To understand their mechanisms of action
- To appreciate their deficiency states
- To recognise groups particularly at risk of deficiency
- To be able to advise customers on supplementation

states are only very rarely seen in western societies.

There are clear guidelines as to what levels should be taken to prevent deficiency syndromes. In the UK, this is the Dietary Reference Value (DRV). It covers the average nutritional need, as defined by prevention of deficiency, of 97 per cent of the healthy population.

Marginal deficiencies are more common, and can have a profound effect on health before clinical deficiencies develop and are diagnosed. Many complementary approaches look for the warning signs of low

Continued on PII →

Table 1: Mechanisms of action of water-soluble vitamins**Vitamin B1** (thiamine)

Coenzyme for thiamine pyrophosphate required for the metabolism of carbohydrofate, fat and alcohol

Vitamin B2

Forms the essential co-enzymes FAD (flavin dinucleotide) and FMN (flavin mononucleotide), required for converting proteins, fats and carbohydrates into energy

Vitamin B3 (niacin)

Niacin forms two co-enzymes, NAD (nicotinamide adenine dinucleotide) and NADP (phosphate form), which are fundamental to energy production

Vitamin B5 (pantothenic acid)

Part of Coenzyme A, a key enzyme required for energy production. Also required by the adrenal gland and in antibody formation

Vitamin B6

Forms part of the co-enzymes pyridoxal phosphate and pyridoxamine phosphate, required for energy production, protein and fat metabolism

Vitamin B12 (cobalamin)

Required for DNA synthesis – vital for cell production and formation of red blood cells.

Folic acid

Many roles. Required for synthesis of DNA and cell division. Required for production of methionine and glycine (non-essential amino acids)

Biotin

Involved in metabolism of carbohydrates and fats. (Needed for energy production). Specifically in lipogenesis (fat formation), gluconeogenesis (formation of glycogen) and metabolism of branched chain amino acids.

Vitamin C

Required for formation of collagen, for growth, tissue repair and wound healing, absorption of iron, formation of antibodies and stimulation of white blood cells, formation of corticosteroid hormones (adrenal gland).

Continued from PI

nutrient levels before clinical deficiency occurs.

From government dietary reports, clinical deficiencies of water-soluble nutrients are an extremely rare occurrence. Explained simply, low blood levels of water-soluble nutrients can result from three main causes – low dietary intakes, poor absorption in the gastrointestinal tract, or factors that increase requirements.

Table 2 lists deficiency

**Table 2: Water-soluble vitamin deficiency syndromes****Vitamin B1**

Orthodox – beriberi (oedema, lactic acidosis, peripheral neuropathy, tachycardia, enlarged heart, vasodilatation, pulmonary congestion, venous distension), Wernicke-Korsakoff syndrome Complementary – tender eyes, eye pains, irritability, poor concentration, 'prickly legs', poor memory, stomach pains, constipation, tingling hands, tachycardia

Vitamin B2

Orthodox – lesions in the mouth (angular stomatitis, cheilosis, atrophic lingual papillae, glossitis, and magenta tongue), skin lesions, surface lesions on genitoilio and corneal vascularisation Complementary – burning or gritty eyes, sensitivity to bright lights, sore tongue, cataracts, dull or oily hair, eczema or dermatitis, split nails, cracked lips

Vitamin B3

Orthodox – Pellagra (lesions on knees, ankles, wrists and elbows, dermatitis, diarrhoea, dementia with intermittent lucidity). Untreated deficiency is fatal Complementary – lack of energy, diarrhoea, insomnia, headaches and migraines, poor memory,

onxiety or tension, depression, irritability, bleeding or tender gums, acne

Vitamin B5

Orthodox – (experimental deficiency) fatigue, headache, dizziness, muscle weakness, gastrointestinal disturbances. No other evidence for deficiency. 'Burning feet syndrome', postural hypotension, impaired response of eosinophils to adrenocorticotrophic hormone

Complementary – muscle tremors or cramps, apathy, poor concentration, burning feet or tender heels, nausea or vomiting, lack of energy, exhaustion after light exercises, anxiety or tension

Vitamin B6

Orthodox – inflammation of the tongue, lip lesions, lesions in the corners of the mouth and peripheral neuropathy

Complementary – sore skin, tingling hands, irritability, lack of energy, flaky skin, depression or nervousness, muscle tremors or cramps

Vitamin B12

Orthodox – nerve damage, pernicious anaemia (weakness, sore tongue, diarrhoea, ataxia, dementia and psychosis) Complementary – bleeding or tender gums, easy bruising, lack of energy, frequent colds, slow wound healing, red pimples on skin, frequent infections

syndromes for each water-soluble vitamin and people at high risk of illness. Both established orthodox research and complementary approaches are listed for comparison.

At risk groups

Research has identified those at high risk of nutritional deficiencies from water-soluble nutrients. The elderly, vegetarians and vegans on poorly planned diets, as well as people who eat little fresh produce, are at risk of deficiencies.

People with food allergies eating erratic diets over a long period of time may also develop nutritional deficiencies, especially if avoiding wheat produce (which is rich in B-vitamins), dairy or citrus foods.

Table 3 lists foods that are rich in the water-soluble nutrients. By following a diet rich in these nutrients, people guard against deficiency syndromes.

People with poor appetites, those on medication that interacts with water-soluble nutrients, or those with digestive disorders are also in danger of developing deficiencies of water-soluble nutrients (see table 4).

Supplementary uses

Sales of nutritional supplements have rocketed over the past five years. Mirroring this is a steady

Continued on PIV ➤

The Pharmacist & Smoking Cessation

WHY YOU SHOULD GET INVOLVED


Smoking is the single greatest cause of preventable illness and premature death in the UK.¹ Seventy per cent of smokers say they want to quit² and each year 36% actively try³, yet only 3% are successful when they rely on willpower alone.⁴

Helping people to quit smoking is now recognised as a top national and local priority. Pharmacists are often the first port of call for smokers thinking about quitting and they have an important role to play in supporting them. Recent research has shown that 1 in 6 people visit a pharmacist when they are planning to stop smoking.⁵

HELPING PATIENTS TO QUIT SUCCESSFULLY

It is now recognised that the majority of smokers do not smoke out of choice, but because they are addicted to nicotine. The power of this addiction was highlighted in the recent Royal College of Physicians report (February 2000), which states that nicotine is as addictive as 'hard drugs' such as heroin or cocaine.⁶

Cycle of Nicotine Addiction^{7,8}



This is the main reason why so few smokers manage to give up without some form of help or support.⁶ Motivation is vital in any attempt to quit, but it is rarely enough on its own. Pharmacological treatment, combined with advice and support, has been shown to be the most effective way to help motivated patients stop smoking.⁴

IDENTIFYING THE MOTIVATED QUITTER

Motivation is very important if an attempt at giving up smoking is to succeed. It is possible to quickly determine whether a smoker is motivated to quit by asking three simple questions:

- 1. Do you want to stop smoking?**
- 2. Is it important for you to stop?**
- 3. Would you be prepared to stop smoking in the next 2 weeks?**

If the smoker answers positively to all three questions, they are motivated and they should be encouraged with help and advice.

Pharmacists are a primary source of advice for patients who may wish to use a pharmacological therapy to assist them in stopping smoking.

PHARMACOLOGICAL THERAPIES

Nicotine Replacement Therapy (NRT)

Until recently, the only licensed pharmacological treatment for smoking cessation was nicotine replacement therapy. NRT works by weaning the patient off nicotine through a controlled

reduction in intake.¹⁰ Overall, clinical trials have indicated that about 1 in 6 smokers (17%) who use NRT are not smoking a year later.¹¹ NRT approximately doubles cessation rates compared with a placebo.

NRT is not suitable for all patients.¹⁰ It is currently recommended that some NRT products should be used with caution in people with heart disease or certain other conditions, including serious cardiac arrhythmias, systemic hypertension and peripheral vascular disease.¹²⁻¹⁴

ZYBAN ▶ (bupropion hydrochloride SR)

Zyban is the first non-nicotine therapy to be licensed for smoking cessation and offers a novel approach to treating nicotine addiction. The drug works in the brain by acting on the neurotransmitters involved in nicotine dependency and withdrawal^{15,16} to reduce the craving for cigarettes and the withdrawal symptoms.¹⁶⁻¹⁷ In a comparative study published in the New England Journal of Medicine, nearly 1 in 3 people (30.3%) who took Zyban were not smoking a year later.¹⁶

Zyban is a prescription-only medicine and should be prescribed as a two-month treatment course. Zyban is generally well tolerated.^{16,18} The most common adverse events seen in clinical trials were dry mouth, headache and insomnia^{16,18}, all of which can also be associated with stopping smoking.^{9,10} Zyban should not be prescribed to certain patients, e.g. those with a seizure disorder or a history of seizures, or those who have a

current or previous diagnosis of eating disorders.

Every patient prescribed Zyban is offered support from the Right Time Programme, which includes tips and advice for quitting, motivational mailings and access to dedicated QUIT counsellors via a free helpline. (QUIT[®] is a national charity and their counsellors are all specialists in smoking cessation.)

THE ROLE OF THE PHARMACIST

Encouragement and support are vital for a successful quit attempt and pharmacists are often the first port of call for smokers planning to give up. Pharmacists play a key role in providing advice for smokers wanting to quit, together with tailoring treatment to meet the needs of individuals by recommending NRT or a referral to a GP.

REFERENCES

- 1 Secretary of State for Health and the Secretaries of State for Scotland, Wales and Northern Ireland. *Smoking kills: A white paper on tobacco*. London: The Stationery Office, November 1998.
- 2 Bridgeford A, Lilly R, Thomas M et al. Living in Britain: Results from the 1998 General Household Survey. Office for National Statistics, Social Survey Division. London: The Stationery Office, 2000.
- 3 West R. *Getting serious about stopping smoking: A review of products, services and techniques*. London: No Smoking Day, March 1997.
- 4 Parrott S, Godfrey C, Raw M et al. Guidance for commissioners on the cost-effectiveness of smoking cessation interventions. *Thorax* 1998; **53** (Suppl. Pt 2): S1-58.
- 5 QoI Survey, October 2000.
- 6 Royal College of Physicians. *Nicotine addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians*. London: Royal College of Physicians, 2000.
- 7 Leslie A. Understanding drug addiction: implications for treatment. *Hosp Pract* 1996; **Oct 15**: 57-59.
- 8 Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. *Primary Care Clinics in Office Practice* 1999; **26**: 653-669.
- 9 Hughes JR, Higgins ST, Hatsukami D. Effects of abstinence from tobacco: A critical review. In: Kozlowski LL, Annis H, Cappell HD et al (eds). *Research advances in tobacco and drug problems*. New York: Plenum Press, 1990; **10**: 117-398.
- 10 Thompson GH, Hunter DA. Nicotine replacement therapy. *Ann Pharmacother* 1998; **32**: 1067-1075.
- 11 Slagay C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2000. Oxford Update Software.
- 12 Raw M, McNeill A, West R. Smokeless cessation guidelines for health professionals. *Thorax* 1998; **53** (Suppl. Pt 2): S1-19.
- 13 Annin. Nicotine replacement to aid smoking cessation. *Drug Ther Bull* 1999; **37**: 57-58.
- 14 Monthly index of medical specialities (MIMS). November 2000.
- 15 Covey LS, Sullivan MA, Johnson JA et al. Advances in non-nicotine pharmacotherapy for smoking cessation. *Drugs* 1999; **59**: 17-31.
- 16 Jorenby DE, Ferri GW, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *NEJM* 1999; **340**: 685-691.
- 17 Data on file, Glaxo Wellcome.
- 18 Hurt RD, Saultz DW, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. *NEJM* 1997; **337**: 1195-1202.

Prescribing Information (PI)

(Please refer to the full SPC before prescribing)

Zyban 150 mg prolonged release tablets (bupropion HCl)

Uses Smoking cessation (with motivational support) in nicotine-dependent patients. **Dosage and administration** Adults from 18 years. Start treatment while still smoking and set target stop date within first two weeks. 150 mg o.d. for 3 days then 150 mg b.d. for remainder of 7 to 9 week course. Maximum 150 mg single dose and 300 mg daily. Allow at least 8 hours between doses. Discontinue if no effect at week 7. Elderly, renal or mild-to-moderate hepatic impairment: 150 mg o.d. **Contraindications** Hypersensitivity, previous/current seizure or eating disorder, recent/current MAOIs, severe hepatic cirrhosis, bipolar disorder. **Precautions** Predisposition to lowered seizure threshold/increased risk of seizures (including previous head injury, brain tumour, other medication, alcohol abuse, diabetes), renal or mild-to-moderate hepatic impairment, elderly susceptibility to psychotic episodes. **Drug interactions** Theophylline, tricyclics, SSRIs, MAOIs, antipsychotics, beta-blockers, class 1C antiarrhythmics, enzyme inducers/inhibitors, orphenadrine, cyclothosphamide, levodopa. **Pregnancy and lactation** Not recommended. **Side effects** Common: dry mouth, constipation, headache, dizziness, depression, agitation, anxiety, rash, pruritis, urticaria, sweating, fever, taste disorders. Uncommon: chest pain, asthenia, tachycardia, blood pressure changes, flushing, confusion, anorexia, tinnitus, visual disturbance. Rare: vasodilation, syncope, seizures, severe hypotension, tachycardia, PL holder Glaxo Wellcome UK Ltd., Stockley Park West, Uxbridge, UB11 1BT.

Table 3: Rich sources of water-soluble vitamins

Vitamin B1	Bread, cereal products, potatoes, milk and meat
Vitamin B2	Milk, meat, fortified cereals, eggs
Vitamin B3	Meat/meat products, potatoes, bread, fortified cereals
Vitamin B5	All animal products, grains and legumes
Vitamin B6	Potatoes, other vegetables, milk and meat
Vitamin B12	All animal products, certain algae and bacteria
Folic acid (folate)	Liver, yeast extract, green leafy vegetables
Biotin	found in a wide range of foods
Vitamin C	Potatoes, fruit juices, citrus fruits, green vegetables

Continued from PII

wave of interest in the use of supplements to improve health, rather than just prevent deficiencies.

Many orthodox scientists argue that western diets provide sufficient amounts of water-soluble nutrients and that supplements are unnecessary. Others, however, feel that supplementation provides consumers with a valuable means to improve their overall health.

Table 5 lists some common supplementary uses for the water-soluble vitamins, together with safety information and contra-indications.

Safe doses

It is well established that water-soluble nutrients are safer than the fat-soluble vitamins A, D, E and K. This is because they are not stored by the body and are efficiently processed by the liver. The body quickly absorbs water-soluble nutrients and easily eliminates excess from the body via the urine.

One water-soluble nutrient that has been in the limelight is vitamin B6. This followed government proposals to limit free sale of vitamin B6 to 10mg. This led to widespread criticism by consumers and industry alike who had followed guidelines laid down in the Shrimpton report.

The Royal Pharmaceutical Society has advised that pharmacists should consider how to advise customers requesting higher doses of pyridoxine, and that they should decide their own policy on the display of products containing daily doses of more than 10mg. Until legislation is

finalised, industry continues to work to the upper safe limits (see Nutrient box).

Vitamin C steals the show

There have also been safety concerns about Vitamin C. Since its discovery in the 1700s, thousands of scientific studies covering both dietary and supplementary intakes have been published.

A report in *Nature* (April 1998) questioned the safety of vitamin C at 500mg daily intakes, the level chosen by the Ministry of Agriculture, Fisheries and Food as the most popular supplement intake.

More research is being carried out to determine the exact intake at which a pro-oxidant effect (the opposite of a beneficial antioxidant effect) predominates. Again, this signals the start of more stringent safety research into water-soluble nutrients and will no doubt come under the same scrutiny and controversy as vitamin B6.

References available on request

C&D is accredited by the College of Pharmacy Practice as a provider of distance learning until March 2001.

Box: Nutrient intakes

	Median Dietary Intake (daily)
Vitamin B1	1.7mg
Vitamin B2	2.0mg
Vitamin B3	
-amide	39.6mg
-acid	39.6mg
Vitamin B5	6.0mg
Vitamin B6	2.4mg
Vitamin B12	7.2mg
Folic acid	300mg
Biotin	37.5mg
Vitamin C	57.6mg

ACTION PLAN

1. The article talks about DRVs and Median Dietary Intake. Your reading will also have exposed the terms RDA and RNI. Find out the meanings of these terms and how they are related.

2. In your practice workbook list the products you sell containing each of the vitamins mentioned in the article. Show those products containing a single vitamin separately. Indicate how much they contain and if this is reasonable in terms of factors mentioned in the article.

3. Discuss the article with your staff and colleagues, and try to come to a consensus of what product and strength you should recommend for each vitamin. This will be complex especially when looking at combined products but try to develop a list of products for conditions presented by patients, eg tiredness, cold protection, treating a cold, lack of energy and so on.

4. Look at the complementary list provided. How do you feel about these indications?

Table 5: Supplementary uses for water-soluble vitamins, with safety information and contra-indications

B Complex Vitamins – vegetarians and vegans (safeguard against deficiency), athletes (energy production, to meet the extra demands of intense physical activity), for maintenance of healthy skin, hair and nails, people with allergies (to safeguard against low intakes)

Vitamin C – healthy immune function, a healthy heart, as an antioxidant, in periods of stress, for healthy skin

Vitamin B1 – to guard against deficiencies caused by a high carbohydrate diet, high alcohol intakes, physical and mental stress

Vitamin B2 – prevention of deficiency (see Table 3). Causes yellow coloration of the urine. May affect the way cancer cells respond to methotrexate. To be taken apart from antibiotics (riboflavin is unstable in the presence of erythromycin and tetracycline)

Vitamin B3 – correction of deficiency, high cholesterol (under supervision), arthritis (joint conditions). At 20mg and more, nicotinic acid may cause flushing (dilation of the blood vessels). Nicotinic acid should not be taken by people suffering from gout, diabetes, stomach ulcers and liver disease

Vitamin B5 – Stress, allergies, arthritis

Vitamin B6 – Women on the pill, drinkers and smokers, women with pre-menstrual problems, nausea, maintenance of healthy nerve function. Not compatible with levodopa, phenytoin and phenobarbitone

Vitamin B12 – Treatment of anaemia, prevention of deficiency in vegans

Folic acid – Prevention of neural tube defects in foetus. For heart health, guard against deficiency in alcoholics, and for megaloblastic anaemia. At very high intakes, interferes with zinc absorption. Consult a GP if on drugs that inhibit folic acid (some cancer treatments) or on anticonvulsant drugs

Biotin – for dermatitis

Vitamin C – infections, after surgery and fracture, for dental and oral conditions, for anaemia (with iron), osteoarthritis, allergies. Corticosteroids, aspirin and birth control pills increase excretion of vitamin C. Dilutes the effect of tricyclic antidepressants. Acidic form not advised for people with kidney stones at intakes greater than 1g/day

Table 4: Risk factors for water-soluble vitamin deficiency

Vitamin B1

Chronically ill, anorexics, chronic alcoholics, people with intestinal malabsorption problems, and those undergoing renal dialysis

Vitamin B2

Anorexics, intestinal malabsorption, chronic alcoholism, biliary atresia, diabetics, patients on chlorpromazine, barbiturates, and thiazide diuretics

Vitamin B3

Hartnup's disease (congenital defect affecting absorption of amino acids), carcinoid syndrome

Vitamin B5

Neither syndrome or causes have been clearly identified

Vitamin B6

Long-term use of isoniazid or penicillamine, oral contraceptives, patients with Parkinson's disease taking levodopa, homocystinuria, chronic renal failure, coeliac

disease, biliary obstruction and chronic alcoholics

Vitamin B12

Inadequate vegetarian and vegan diets, diverticulosis, Crohn's disease, inflammation of the ileum, ileal strictures or fistulas, scleroderma with abnormal gut motility, continued use of antibiotics

Folic acid

Elderly people with poor diets, alcoholics, coeliacs, multiple pregnancies, unsupplemented lactation, and haemolytic anaemia

Biotin

Improper use of total parenteral nutrition in hospitals. People consuming large amounts of raw eggs

Vitamin C

Severe coeliacs, chronic alcoholics, rheumatoid arthritis, anorectic patients with cancer, heavy smokers.

Prescribing Information
Please refer to the full
(PC before prescribing)
Zyban 150 mg
extended-release tablets
bupropion HCl

uses Smoking cessation (with motivational support) in nicotine-dependent patients.
usage and administration Adults from 18 years: Start treatment while still smoking and set 'target stop date' within first two weeks. 150 mg o.d. for 3 days then 100 mg b.d. for remainder of 7 to 9 week course. Maximum 150 mg single dose and 100 mg daily. Allow at least 8 hours between doses. Review at week 7; continue if no effect. **Elderly, renal or mild-to-moderate hepatic impairment:** 100 mg o.d. **Contra-indications** Hypersensitivity, previous/current seizure or fitting disorder, recent/current MAOIs, severe hepatic cirrhosis, bipolar disorder. **cautions** Predisposition to lowered seizure threshold/increased risk of seizures (including previous head injury, brain tumour, other medications, alcohol abuse, diabetes), renal or mild-to-moderate hepatic impairment, elderly, susceptibility to psychotic episodes. **Drug interactions** Theophylline, tricyclics, SSRIs, MAOIs, antipsychotics, beta-blockers, class Ic antiarrhythmics, enzyme inducers/inhibitors, orphenadrine, cyclophosphamide, L-dopa. **Pregnancy and lactation** Not recommended. **Side effects** Common: dry mouth, gastrointestinal pain/upset, drowsiness, tremor, concentration disturbance, headache, dizziness, depression, agitation, anxiety, rash, pruritus, urticaria, sweating, taste disorders. Uncommon: chest pain, asthenia, tachycardia, blood pressure changes, flushing, confusion, anorexia, constipation, visual disturbance. Rare: vasodilation, headache, seizures, severe hypersensitivity reactions including anaphylaxis, arthralgia, myalgia and fever, erythema multiforme, Stevens Johnson syndrome. **Presentation**
Basic NHS cost 60 tablets £42.85.
Product Licence (PL) no. PL10949/0340.
Holder Glaxo Wellcome UK Ltd.,
Oakley Park West, Uxbridge, UB11 1BT.
M


Further information is available from:
Glaxo Wellcome UK Limited,
Oakley Park West, Uxbridge, UB11 1BT.
Email: customerservices@glaxowellcome.co.uk
Telephone: 0800 221 441.
Glaxo Wellcome UK Limited, 2000.
Zyban and the Zyban logo are trade marks
of the Glaxo Wellcome Group of Companies.

References
1. Leschner AI. Hosp Pract 1996, Oct 15: 7-59.
2. Jerry LH. Primary Care Clinics in Office Practice 1999; **26**: 653-669.
3. Moye LS, Sullivan MA, Johnston JA, et al. Drugs 2000; **59**: 17-31.
4. Orenby DE, Leischow SJ, Nides MA, et al. J Engl J Med 1999; **340**: 685-691.

GlaxoWellcome

FOR SMOKING CESSATION

Z MARKS THE SPOT



Nicotine addiction is a neurobiologically-mediated brain disease.¹ Zyban is a unique non-nicotine tablet therapy that works in the brain by acting on the neurotransmitters involved in nicotine addiction and withdrawal.^{2,3} In a trial published in The New England Journal of Medicine, Zyban was shown to be almost twice as effective as a nicotine patch in achieving smoking abstinence at one year.⁴

• NEW
Zyban
bupropion HCl SR

Science against smoking

No go zone

Constipation is a subject that pharmacists come across every day. The second in a series of articles taken from TESEMED, the European electronic self-medication programme for pharmacists, provides all the information they need

Constipation is defined as a decreased frequency of bowel movements, with hard stools often passed with difficulty and straining.

The normal frequency of bowel movements varies between individuals, from twice daily to once every two or three days. Constipation therefore, means different things to different people and it is important for the pharmacist to find out exactly what the patient understands by constipation to ensure that the problem is real.

Typically, there is accumulation of hard, dry material in the descending colon, so that reabsorption of water takes place over a long period, with the result that the faeces have a low water content. Reabsorption of water from the faeces may be due to:

- Active transport of sodium
- Absorption of bicarbonate ions into the duodenum and jejunum
- Absorption of bicarbonate ions into the ileum and large intestine, with simultaneous absorption of chloride
- Ion movement across the intestinal membrane.

Causes of constipation range from simple changes in lifestyle and daily routine to major bowel or systemic disease (see table 1). Medicines can also induce iatrogenic constipation (see table 2).

Referral situations

When one of the following symptoms occur, the pharmacist needs to refer the patient to their GP. This is important, as most of the major diseases that may give rise to constipation need urgent treatment.

General malaise

If the patient feels ill, weak and unable to work while constipated, they should be referred to a doctor to exclude any other organic causes.

If babies or older children become irritable, feverish, drowsy



Constipation is a common problem for both the young and old

or have pain, eat less or vomit, they should be referred.

Blood in the stool

This symptom is not necessarily serious. If the blood appears fresh and is present only on the surface of the stool, it is most likely to have come from the anus or the distal part of the colon, probably because of straining.

Patients should be referred if:

- The blood is mixed with faeces giving it a dark colour often described as 'tar'. This may have a more serious underlying cause such as diverticulitis, a bleeding peptic ulcer, or in rare cases a carcinoma.
- The blood appears as specks or as a light smear on the toilet paper after a bowel movement and a previous diagnosis of haemorrhoids or a similar condition has been made.
- Straining and hard stools due to concomitant constipation can cause or exacerbate haemorrhoids. In this case, a referral may also be necessary.

It is usually prudent to refer all patients with rectal bleeding for assessment of the cause.

Patients taking iron and

bismuth tablets often have darkened stools, which is of no consequence.

Severe pain

Continuous or severe abdominal pain accompanying constipation, lasting for two days or more, usually requires a medical opinion. It could be due to bowel obstruction caused by a tumour, diverticular disease or irritable bowel syndrome.

Weight loss

Weight loss combined with constipation is common to many serious diseases, so it is advisable to refer to a doctor to exclude malignancy.

Diarrhoea

Although it sounds paradoxical, diarrhoea and constipation sometimes co-exist or alternate. In young adults, this situation together with abdominal pain is typical of irritable bowel syndrome. In elderly patients, such symptoms suggest diarrhoea secondary to faecal impaction.

Rectal tenesmus

Continuous painful and ineffective need to defecate. It could be due to irritable bowel syndrome or other major diseases.



THE COLLEGE OF PHARMACY PRACTICE

THIS COURSE (MODULE 1185), IN ASSOCIATION WITH MULTIPLE CHOICE QUESTIONS BEING PUBLISHED IN C&D JANUARY 2001, PROVIDES ONE HOUR'S CONTINUING EDUCATION

OBJECTIVES

- To recognise causes of constipation
- To understand laxatives' mechanisms of action
- To recognise drugs that can cause constipation
- To know which laxatives are best for individual patients
- To be able to advise patients about laxatives

Persistent symptoms or failure of OTC medicines

If symptoms persist for more than one to two weeks, or if self-medication with OTC medicines has not been effective, the patient must be referred.



Treatment

Constipation not caused by serious pathology will usually respond to simple measures. The first-line recommendation is to adopt an appropriate diet and lifestyle. Second-line treatment is laxatives.

Drug treatment

Continuous drug use – especially of stimulant laxatives – may result in a vicious circle where the contents of the gut are expelled, causing a subsequent cessation of bowel action for one or two days. This may give the impression that constipation has recurred, causing the patient to take more laxatives.

Chronic overuse of stimulant laxatives may result in loss of muscular activity in the bowel wall (atonic colon) and further constipation.

Continued use of laxatives can also lead to a psychological dependence. It is therefore important to stress that no treatment should be taken for a prolonged period.

It is important to find out whether the patient is suffering from any concomitant diseases. There are situations where straining may exacerbate the patient's condition (such as angina pectoris) or increase the risk of

Table 1: Causes of constipation

Diet and lifestyle

- Changes in eating, such as reduced fibre intake (particularly fruit and vegetables)
- Reduced overall intake, as in a diet or illness
- Reduced fluid intake
- Changes in lifestyle: job changes, loss of work or retirement, travel, changes in daily routine, stress, and lack of exercise

Disorders of the digestive tract

- Gastric disorders (eg cancer, gastric stricture)
- Intestinal disorders (eg diverticulosis, intestinal obstruction, irritable bowel syndrome, cancer of the colon, parasitosis, tuberculosis, syphilis)
- Rectal disorders (eg cancer, ulcerous proctitis)
- Anal disorders (eg fissures, abscesses, stenosis and complicated haemorrhoids)

Other conditions

- Pregnancy
- Endocrine and metabolic disorders (eg hypercalcaemia, hypothyroidism, uraemia, diabetes, porphyria and phaeochromocytoma)
- Neurological disorders (eg Parkinson's disease, medullary lesions, and cerebrovascular accident)
- Pulmonary disorder (eg chronic respiratory insufficiency, emphysema)
- Diaphragm dysfunction
- Muscular disorders, abdominal hernia
- Peritoneal disorders (eg ascites)
- Gynaecological disorders (eg ovarian cysts)
- Systemic conditions (eg malnutrition, anorexia, cachexia)

rectal bleeding (such as haemorrhoids).

Laxatives can be divided into five categories, according to their mode of action:

- Bulk laxatives
- Stimulant laxatives
- Osmotic laxatives
- Faecal softeners
- Lubricant laxatives.

Bulk laxatives

These include wheat bran, methylcellulose, ispaghula husk, and *Sterculia urens*.

Bulk-forming laxatives provide the closest approximation to the natural process of increasing faecal volume, and are normally the first line recommendation for functional constipation. They contain natural or semi-synthetic polysaccharides or cellulose

derivatives that pass through the gastrointestinal tract undigested.

All bulk-forming laxatives are more or less equally effective, but patients find some preparations more palatable than others.

These products increase faecal volume in order to stimulate peristalsis. They work through three different mechanisms.

● The first action is to add directly to the volume of the intestinal contents; bran consists almost entirely of water-insoluble fibre and acts in this way.

● Other bulk-forming laxatives contain mucilaginous constituents that bind to water and swell in the colonic lumen forming a gel, thereby softening the faeces and increasing their bulk. This is the case for ispaghula husk (consisting of the seeds of various species of plantago), linseed, psyllium seed and sterquilin (also known as Indian tragacanth or karaya gum – from the tropical shrub *Sterculia urens*).

Methylcellulose, which forms a semi-synthetic hydrophilic colloid, has a similar action.

● Bulk laxatives also add to faecal mass by acting as substrates for the growth of bacteria in the colon.

Usage and administration

These types of laxatives should not be taken immediately before going to bed. This is due to the risk of oesophageal blockage.

They have a slow action, usually acting within 24 hours, but two or three days' medication may sometimes be required to achieve their full effect.

Bulk laxatives are often recommended in patients with inadequate fibre intake, or suffering from an irritable bowel syndrome or haemorrhoids, or in the management of elderly people.

Cautions and contra-indications

Bulk-forming laxatives should be avoided if the patient suffers from a diverticular disease or bowel obstruction.

As they are not absorbed, these laxatives have no systemic effect and usually do not interact with other medicines. However, they can interfere with the absorption of some ingredients like digoxin and nitrofurantoin.

There is a risk of oesophageal and intestinal obstruction if preparations are not taken with plenty of water.

Bulk-forming laxatives may cause discomfort if taken in the later stages of pregnancy, as abdominal distension and flatulence are possible side effects.

Some products contain glucose,

which needs to be taken into account for diabetic patients. Bran contains gluten and should not be taken by patients with coeliac disease or gluten enteropathy. The sodium content of bulk laxatives should be considered in people requiring a restricted sodium intake.

Stimulant laxatives

Stimulant laxatives can be divided into two

main groups based on their different chemical structures and nature of the ingredients. Some of the best known ingredients are:

Anthraquinones

Senna

Aloin

Fragaria

Cascara

Powdered rhubarb

Diphenylmethane derivatives

Bisacodyl

Sodium picosulphate

Phenolphthalein.

Among the traditionally-used stimulant laxatives, castor oil has fallen into disuse because of its 'drowsy' action and unpleasant taste.

Mode of action

Stimulant laxatives are believed to stimulate nerve endings in the nerve plexuses of the bowel wall, increasing peristalsis. This is achieved through one or both of two possible mechanisms.

The first is inhibition of the 'sodium pump' (the enzyme sodium/potassium adenosine triphosphatase [Na^+K^+ -ATPase]). Inhibition of the sodium pump prevents sodium transport across the intestinal wall and leads to the accumulation of water and electrolytes in the gut lumen.

A second mechanism is increased production of fluid in the intestine through the action of the laxative on cyclic adenosine monophosphate (cyclic AMP) and prostaglandins, which promote active secretory processes in the intestinal mucosa.

It is also thought that stimulant laxatives may cause direct damage to mucosal cells thereby increasing the permeability of these cells and allowing fluid to leak out.

Usage and administration

Stimulant laxatives are usually taken at bedtime to produce an effect the following morning. Suppository presentations (eg bisacodyl)

produce much faster results, usually within an hour.

The length of time for individual stimulant laxatives to take effect varies according to their site of action, which may be in the small

intestine, the large intestine or both. But they normally work within 4-12 hours of administration.



Cautions and contra-indications

The main adverse effects of stimulant laxatives are griping and intestinal cramps. Prolonged use may result in fluid and electrolyte imbalance, and loss of colonic smooth muscle tone. This in turn may lead to a vicious circle in which increasingly larger doses of laxatives are needed to produce evacuation until eventually the bowel ceases to respond at all and constipation becomes permanent.

Stimulant laxatives should be avoided in the first quarter of pregnancy. Anthraquinones are secreted in breast milk, and large doses may cause increased gastric motility and diarrhoea in breastfed infants. Breastfeeding mothers should, therefore, avoid this class of laxative.

Anthraquinone glycosides are excreted via the kidney and may colour the urine a yellowish-brown to red colour, depending on its pH.

Although many stimulant laxatives carry dosage schedules for children, they should be used with caution.

Anthraquinones

Anthraquinones are naturally occurring glycosides used in the form of standardised plant extracts. They are believed to act through a combination of direct stimulation of the intramural nerve plexus and interference with absorption of water across the intestinal wall. The effects of individual preparations vary according to the speed of hydrolysis of the glycosides they contain and their anthraquinone constituents.

Senna is obtained from the dried leaves or pods of *Cassia senna acutifolia*, or *Cassia angustifolia*. Preparations are usually standardised to the content of sennoside B (7.5mg per tablet or per 5ml syrup). The use of senna pods should be avoided.

Aloin is an extract of aloes. It has a similar but more drastic action to senna and is more irritant.

Other anthraquinone plant derivatives used in non-prescription laxative products include powdered rhubarb (a 'soft' laxative), frangula from the bark of *Rhamnus frangula*, and Cascara from *Cascara sagrada*.

Diphenylmethane derivatives

Bisacodyl acts mainly via stimulation of the mucosal nerve

Continued on PVIII →

Continued from PVII

plexus of the large intestine, so takes rather longer to act (six to 10 hours after oral administration) than laxatives that act within the small intestine. The action is faster if taken as a suppository (from 20 minutes to one hour).

It is minimally absorbed and appears to exert no systemic effects. As bisacodyl causes gastric irritation, it is not available in liquid form and tablets are enteric-coated.

Sodium picosulphate, structurally related to bisacodyl, becomes active following metabolism by colonic bacteria. It therefore has a relatively slow onset of action, usually acting within 10 to 14 hours. It can be used in young children.

Phenolphthalein used to be one of the most common ingredients in laxative products marketed for non-prescription medicines sale, but due to its adverse effects it has been retired from the market in most European countries.

It is a chemical closely related to bisacodyl and sodium picosulphate. The medicine is partly absorbed in the intestine, taken up by the bile salts and repeatedly recycled through the liver, so that a single dose may exert an effect for several days. Phenolphthalein commonly causes a rash and colours the urine pink and faeces red, which may alarm patients. Adverse effects including albuminuria and haemoglobinuria may also occur.

Osmotic laxatives

The most commonly used osmotic laxatives include magnesium hydroxide, sodium potassium tartrate, lactulose and glycerol.

Mode of action

Osmotic laxatives are either inorganic salts (magnesium hydroxide), or organic ingredients (loctitol, lactulose, glycerol). Like the bulk laxatives, they retain fluid within the bowel to stimulate peristalsis and the formation of soft stool.

They are poorly absorbed from the intestine, where their presence creates a hypertonic state. In order to equalise osmotic pressure, water is drawn from the intestinal wall into the lumen, raising the intraluminal pressure by increasing the volume of the contents. This stimulates peristalsis and promotes evacuation. They tend to have a more powerful action than the bulk laxatives.

Usage and administration

The inorganic salts produce effects within three hours. They are also believed to act through stimulating the secretion of the hormone cholecystokinin, which promotes fluid secretion and motility in the intestine.

Lactulose is a synthetic disaccharide. It takes much longer to act than the inorganic osmotic laxatives, as it first has to be broken down by colonic bacteria, mainly to lactic acid. This produces a local osmotic effect.

It may take 72 hours of regular dosing to produce an effect. It has a sweet taste which makes it more palatable for children, to whom it can be safely given, but many adults find the larger volumes required (up to 30ml) sickly and a deterrent to compliance.

Glycerol is a highly hygroscopic trihydric alcohol. Administered as suppositories, it is believed to act by both a local osmotic action and a stimulant effect. It can be confidently recommended for children and should produce a bowel action within one or two hours.

Cautions and side effects

Some absorption of inorganic laxative salt ions does occur, but in normal healthy individuals the amounts are too small to cause toxic effects, and the ions are rapidly excreted via the kidneys.

However, accumulation of magnesium ions can occur in the presence of renal impairment, causing toxic effects in the central nervous system and altered neuromuscular function through hypermagnesaemia. Except as single treatment, inorganic laxatives are best avoided in patients with chronic renal disease. As renal function tends to decline with age, it may be advisable to discourage regular use by elderly patients.

The main side effects of inorganic laxatives are nausea and vomiting. In addition, large dosages can produce significant dehydration, so sufficient water should always be taken.

Serious adverse effects with lactulose are rare. Relatively minor side effects, although they may be sufficient to discourage compliance, occur in about 20 per cent of patients taking full doses and include flatulence, cramp and abdominal discomfort, particularly at the start of treatment.

Loctitol is a disaccharide of galactose and fructose, and includes some lactose. It cannot, therefore, be used by patients with galactose or lactose intolerance.

Table 2: Drugs that cause constipation

- Antacids: aluminium salts
- Antiepileptics: phenytoin
- Antiemetics: 5-HT3 antagonists including ondansetron, granisetron and tropisetron
- Antihypertensives: clonidine, prazosin, methyldopa, verapamil, and beta blockers
- Antiparkinsonians: levodopa, specific anticholinergics such as biperiden, procyclidine, and trihexyphenidyl, and non-specific anticholinergics such as diphenhydramine, and benzatropine
- Orally administered iron salts
- Atropine and its derivatives
- Tricyclic antidepressants and MAO inhibitors
- Antitussives: opiates such as codeine, dextromethorphan and dihydrocodeine
- Diuretics (when they cause dehydration)
- Antidiarrhoeals (when used inappropriately)
- Opiate analgesics
- Neuroleptics: dibenzodiazepines such as clozapine, olanzapine, and phenothiazines such as chlorpromazine, thioridazine, pimozide, trifluoperazine, and fluphenazine
- Cytoprotectants: bismuth salts, sucralfate
- Cationic resins: cholestyramine
- TESEMED is an electronic self-medication training programme for pharmacists that has been developed in Europe.

The programme is part of a European Commission research programme aimed at improving the public's health knowledge and self-medication throughout Europe. The European organisations representing community pharmacists (PGEU) and the manufacturers of non-prescription medicines (AESGP) are both involved in the project.

Pharmacists are invited by TESEMED to use its web site, the address is www.imim.es/tesemed

and must be used with caution in patients with diabetes.

Faecal softeners

Docusate sodium is an ionic surfactant that acts by lowering the surface tension of the intestinal contents. This allows fluid and fat to penetrate, emulsify and soften faecal material for easier elimination. The faeces are kept

Abridged Prescribing Information
 (Please refer to full data sheets/summaries product characteristics before prescribing)
Beclazone 50, 100, 250mcg Easi-Breathe® Inhaler (beclomethasone dipropionate) Uses Topically applied corticosteroid for prophylactic management of mild moderate or severe asthma. Dosage and administration For inhalation only. Use regular Adults: Beclazone 50 and 100mcg - 400 to 800 mcg daily in divided doses. Beclazone 250mcg - 1,000 2,000mcg daily in divided doses. Children: 200 400mcg daily in divided doses. The dose should be titrated to the lowest dose at which effective control of asthma is maintained. Beclazone 250 Easi-Breathe Inhaler is not recommended for children. Contra-indications Hypersensitivity. Special care active or quiescent pulmonary tuberculosis. Precautions Severe or unstable asthma: We advise patients to seek medical advice if short-acting inhaled bronchodilator use increases or becomes less effective. Consider using oral steroids and/or maximum doses of inhaled corticosteroids. Treat severe exacerbations in the normal way. Acute symptoms: Not for relief of acute symptom. A short-acting inhaled bronchodilator is required. Systemic effects: Systemic effects may occur particularly at high doses prescribed for prolonged periods, but are much less likely to occur than with oral corticosteroids. These may include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Prolonged treatment with high doses, particularly higher than recommended doses, may result in clinically significant adrenal suppression. Titrate dose to lowest dose at which effective control of asthma is maintained. Regular monitoring of height of children receiving prolonged treatment with inhaled corticosteroids. Transient oral steroids: Special care is needed. Monitor adrenal function. Do not stop Beclazone Easi-Breathe Inhaler abruptly. Consider addition of corticosteroid therapy in situations likely to produce stress. Pregnancy and lactation: Experience limited. Balance risks against benefits. Side effects Hypersensitivity reactions. Systemic effects may occur, particularly at high doses prescribed for prolonged periods. Candidiasis of mouth and throat. Hoarseness or throat irritation. Paradoxical bronchospasm: Substitute alternative therapy. Presentation and basic NHS cost Beclazone Easi-Breathe (with Optimiser): 200 actuations: 50mcg: £4.34, 100mcg: £8.24, 250mcg: £18.02. Product licence/marketing authorisation numbers PL 05 0624-6 Product licence/marketing authorisation holder Norton Healthcare Limited, Albert Basin, Royal Docks, London, E16 2QJ

Salamol Easi-Breathe Inhaler (salbutamol) Uses Short-acting bronchodilator used in the management of asthma, bronchospasm and/or reversible airway obstruction. Use of regular inhaled corticosteroid therapy should not be delayed. Dosage and administration For inhalation only. One or two inhalations (100-200mcg). Not more than 8 inhalations in 24 hours. Contra-indications Threatened abortion. Hypersensitivity. Precautions Severe unstable asthma: Bronchodilators should not be the only or main treatment. Consider using maximum doses of inhaled steroids and/or oral steroid. Short-acting bronchodilators become less effective or use increases. Treat severe exacerbations in the normal way. Thyrotoxicosis: Use with caution. Drug interactions: Avoid beta-blockers. Hypokalaemia may occur, particularly in acute severe asthma. May be potentiated by hypoxia and xanthine derivatives, steroids or diuretics. Monitor serum potassium levels. Pregnancy and lactation: Experience is limited. Balance risks against benefits. Side effects Mild tremor, headache and occasionally tachycardia with or without peripheral vasodilation may occur. Cardiac arrhythmias have been reported, usually in susceptible patients. Muscle cramps and hypersensitivity reactions are very rarely reported. Potentially serious hypokalaemia may result from β_2 -agonist therapy. Mouth and throat irritation may occur. Rare reports of hyperactivity in children. Paradoxical bronchospasm: Substitute alternative therapy. Presentation and basic NHS cost Salamol Easi-Breathe Inhaler: 200 actuations: 100mcg: £6.30. Product licence/marketing authorisation number PL/0530/0623 Product licence/marketing authorisation holder Norton Healthcare Limited, Albert Basin, Royal Docks, E16 2QJ

Easi-Breathe is a registered trademark and Beclazone and Salamol are trademarks of Norton Healthcare Limited. Beclotide, Becloforte and Ventolin are trademarks of the Glaxo Wellcome Group of Companies

Continued on PXI →

PLEASE MAKE SURE
YOU UPDATE YOUR
PRESCRIBING SYSTEM
NOW TO REFLECT
THESE NAME CHANGES

Easi-Breathe®

FROM BAKER NORTON

FOLLOWING A MUTUAL AGREEMENT BETWEEN BAKER NORTON AND GLAXO WELLCOME

**BAKER NORTON WILL BE RESUMING RESPONSIBILITY
FOR THE SALES & MARKETING OF EASI-BREATHE.**

PREScriptions FOR ALLEN & HANBURY'S EASI-BREATHE PRODUCTS SHOULD NOW BE CHANGING
TO THE APPROPRIATE BAKER NORTON EASI-BREATHE AS DETAILED BELOW.


ORDER PLACEMENT DETAILS



IS REPLACED BY



IS REPLACED BY



IS REPLACED BY



IS REPLACED BY



PIP CODE 216-9290
U/CHEM
PROSPER CODE 006171
AAH LINK CODE BEC99U



PIP CODE 216-9308
U/CHEM
PROSPER CODE 006312
AAH LINK CODE BEC98B

FOR PATIENTS WHO ARE CONCERNED ABOUT THE CHANGE TO THEIR PRESCRIPTION,
THERE IS AN INFORMATION LEAFLET AVAILABLE. THIS SHOULD REASSURE THEM
THAT THERE HAS BEEN NO CHANGE TO THEIR MEDICATION.

**TO DOWNLOAD THE LEAFLET OR REQUEST ANY FURTHER INFORMATION
VISIT THE WEBSITE @WWW.EASI-BREATHE.COM (PASSWORD IS SWITCH ON)**

EMAIL US ON EASI.BREATHE@NORTONHC.CO.UK OR CALL OUR FREEPHONE HELPLINE ON 0800 0286986

Profit from our experience

The first multi-action supplement range from Nutricia


A whole new range of nutritional supplements,
a whole new opportunity for you



Introducing a new, multi-action approach to help maintain a healthy body through nutritional support and supplementation. Developed by nutritional experts, the Nutricia range is designed to help maintain good health at different life stages. Every nutrient is supported by published evidence.

Each product has two or more ways of working. For example:-

Efalex



The range includes supplements to help maintain healthy bones, healthy heart, healthy eyes, hormonal balance, iron intake and brain function. We also offer multivitamin supplements for men's and women's health, pregnant and breast feeding women, and an antioxidant formula.



The Nutricia range is backed by a £1 million spend on consumer and trade advertising, targeted mailings and POS. We will also be instigating a specific educational programme to Healthcare Professionals to raise awareness of the benefits of supplementation. Nutricia. No-one is more serious about nutritional support.

NUTRICIA SUPPLEMENTS
The science of well-being

Continued from PVIII

soft, and evacuation is achieved without straining. Docusate is also thought to exert a stimulant laxative effect similar to that of the anthraquinones.

Docusate is non-absorbable and non-toxic, but is believed to facilitate the transport of the medicines, including liquid paraffin, across the intestine and could thereby increase its action and adverse effects.

Usage and administration

A laxative effect usually occurs within one to three days of administration. Used alone, docusate is a weak laxative, but it is considered useful for patients in whom straining at stool must be avoided (for example, following an operation or a myocardial infarction, or in patients suffering from hernia).

Faecal lubricants

Liquid paraffin is indigestible and absorbed only to a small extent. It penetrates and softens the faeces, and coats the surface with an oil film, which facilitates its passage through the intestine.

It is considered to have a usefulness as an occasional laxative in situations where straining at the stool must be avoided, but it has several drawbacks which make it unsuitable for regular use.

Cautions and side effects

Liquid paraffin can enter the lung through aspiration and cause lipid pneumonia, so it must not be administered at bedtime or to very young, elderly or debilitated patients. Liquid paraffin may interfere with the absorption of fat-soluble vitamins A, D, E and K.

Decreased vitamin K absorption is particularly significant for patients taking oral anticoagulants, as their effect may be increased. It is slightly absorbed into the intestinal wall where it may set up foreign body



The elderly often avoid high-fibre foods that are difficult to chew

granulomatous reactions. Liquid paraffin may seep from the anus and cause irritation. It should be avoided in cases of abdominal pain, nausea or vomiting, and should never be used for children.

Hygienic measures

Dietary fibre is the treatment of choice for constipation. However the side effects of a high-fibre diet (including bloating, flatulence and irregular bowel movements) may reduce patient compliance. Fibre intake is generally lower in the northern countries than in the countries of southern Europe.

Since low fluid intake also plays an important role in constipation, the patient should drink at least 1.5l of fluid a day, with increased intake in the summer.

Regular bowel movement and physical exercise are important. In case of limited mobility, simply maintaining an upright position may be helpful.

Application of Vaseline to the anal region before defecation is a useful measure to reduce the pain and irritation caused by passage of the dry hard faeces.

Special patient categories

Pregnancy and breastfeeding woman

It has been estimated that one in three pregnant women suffers from constipation. The main cause of constipation in pregnancy is the

increased quantity of circulating progesterone (especially during the second and the third trimesters). This causes relaxation of the smooth muscle of the bowel which, together with the physical compression of the bowel by the growing uterus and the effects of iron therapy, often results in constipation.

Bulk laxatives can be used in pregnancy, as can stimulant laxatives, although the latter are to be avoided in the first quarter. Breastfeeding women should not take anthraquinones as they are secreted in breast milk.

Children

Breastfeeding babies normally produce fewer stools than bottle-fed babies. This is perfectly normal and does not require any intervention. Constipation in a bottle-fed baby may be caused by insufficient water being added to the milk powder.

If babies or older children become irritable, feverish, drowsy, have pain, eat less or vomit they should be referred. If none of these situations apply, it could be sufficient to add more fibre to the diet as children usually respond better and quicker than adults to dietary changes.

The elderly

Constipation is a common problem in elderly patients for several reasons. The elderly are less likely to be physically active. They often have poor or false teeth, and so avoid high-fibre foods that

are more difficult to chew. Many suffer from medicine-induced constipation. Muscle tone in the bowel is usually reduced with increasing age, and faecal stasis may occur.

Elderly patients are often obsessed with 'regular' bowel movement and are therefore more likely to take laxatives not only to restore normal bowel function, but also to prevent constipation. This in turn may lead to laxative abuse that can result in chronic constipation and damage bowel muscle tone.

Nevertheless, constipation in the elderly should be taken seriously as it may indicate dehydration. A bowel filled with impacted faeces may compress adjacent structures such as the urinary tract and cause urinary retention. When this occurs, bulk laxatives are recommended. However, it is important that a proper diet or sufficient fluid intake to prevent a bowel obstruction is recommended.

C&D is accredited by the College of Pharmacy Practice as a provider of distance learning until March 2001.

ACTION PLAN

- Over the next four weeks record in your practice workbook by condition (eg constipation, cold, corn) all patients you provide with a response to a symptom.
- Analyse this list and note the percentage of consultations for each condition
- Also record the number of times you sell a laxative both from a direct request and on your advice.
- Do you suspect there are patients who may be laxative abusers? If so, what do you do?

Discuss this with local colleagues. Would it be advantageous for pharmacists in your locality to cease to supply such abusers?

- What is the drastic action of castor oil? Find out.
- Why are stimulant laxatives taken at night? Is there a sound reason?
- Some experts are questioning the practice of using lactulose so freely in the elderly. Why?

PHARMACYupdate: distance learning for pharmacists

Pharmacists using Pharmacy Update for continuing education are reminded of the need to test. With the support of Genus Pharmaceuticals, C&D's readers can self-test their progress by using the multiple choice question (MCQ) paper to be inserted in the January 13 issue,

which will cover this week's CPP-accredited modules, together with those in the December 16 issue.

The MCQ paper for the November modules will be enclosed in next week's C&D covering:

- Haemorrhoids (1181)
- Trace elements (1182)

- Multiple sclerosis (1183).

A faxback service for these modules and associated MCQs operates on 0891 444791 (premium rates apply). A telephone marking service offers independent verification of results – details are given on the monthly MCQ papers.

C&D in association with



GENUS PHARMACEUTICALS

The Young Ones

Extra care is required when dispensing medicines for children. Recent recommendations concerning the use of medicines that are not licensed for use in children are presented here

Guidelines on using medicines in children were produced last year by a joint committee of the Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group. They were first published in the national paediatric formulary 'Medicines for Children'.

The Committee recommends that those who prescribe for a child should choose the medicine that offers the best prospect of benefit for that child, with due regard to cost.

It also makes recommendations with regard to:

- licensing
- information
- consent
- NHS Trust policies.

Licensing

The informed use of unlicensed medicines or of licensed medicines for unlicensed applications is necessary in paediatric practice.

1. Children may be prescribed unlicensed medicines or medicines that have only been licensed for use in adults when there is no suitable alternative.

2. The Medicines Act includes exemptions, which enables doctors to:

- Prescribe unlicensed medicines
- Use unlicensed products specially prepared, imported or supplied in 'named patients'
- Use medicines in clinical trials
- Use licensed medicines for indications, doses, or routes of administration, outside the licence
- Override the warnings and the precautions given in the licence.
- 3. In each case the doctor has to be able to justify the action taken as being in accordance with a respectable, responsible body of professional opinion.

Information

It is essential that health professionals should have ready access to sound information on any medicine they prescribe, dispense or administer, and on its availability.



1. When the medicine is unlicensed, information on the use of the product will not be available in the marketing authorisation and must be sought elsewhere. Information is often available, although it might not be easily accessible.

2. To meet the need for accessible information and guidance the Committee has prepared a new formulary - 'Medicines for Children'.

3. Parents, patients and teachers need information about medicines from health professionals, including pharmacists. The information must be given in an understandable manner, and be accurate and consistent. This is particularly important when the specialist hands over the care of the patient to someone else. Given the complexity of some of the information, there is a need for practical communication arrangements as well as available reference sources.

Consent of parents, carers and patients

We consider that in general it is not necessary to take additional steps, beyond those taken when prescribing licensed medicines, to obtain the consent of parents, carers and child patients to prescribe or administer unlicensed medicines or licensed medicines for unlicensed applications.

each instance, practice is guided by clinical judgement.

Policies of NHS Trusts

We consider that NHS Trusts should support therapeutic practices that are advocated by a respectable, responsible body of professional opinion.

1. Some NHS Trusts have suggested that clinicians should not use medicines for unlicensed applications. The Department of Health does not expect health authorities to restrict a clinician's freedom to prescribe by directing its medical staff against such action.

2. Within the framework of clinical governance, Trusts may be encouraged to introduce systems and protocols to monitor, and even direct, the use of licensed and unlicensed medicines. Current exemptions in the Medicines Act mean the prescription of an unlicensed medicine is not considered to be a breach of the duty of care if that treatment was supported by a respected body of medical opinion. The best evidence available should always inform the prescriber of medicines for children.

● 'Medicines for Children' (ISBN 1-900954-38-9) is available from B&MBC Books, telephone 01425 471525.

● The generic patient information leaflets may be downloaded from the RCPCH web site: www.rcpch.ac.uk/library or by writing to the college at 50, Hollow St, London W1W 6DE.

References

1. 'A paediatrician's guide to the UN Convention on the Rights of the Child'. London: British Paediatric Association, 1995.
2. A Report of the Joint Working Party of the British Paediatric Association and the Association of the British Pharmaceutical Industry: 'Licensing Medicines for Children'. London: Royal College of Paediatrics and Child Health, 1996.
3. 'Good Medical Practice'. London: The General Medical Council, 1998.
4. 'Seeking patients' consent: the ethical considerations'. London: The General Medical Council, 1999.
5. 'Letter to the President, British Paediatric Association 3 November 1993'. Department of Health.

ntional TV advertising
50 Stock up now



A 50% increase in sales makes Olbas Inhaler
a leading decongestant in pharmacy.

Source: AC Nielsen March/April 2000

Call our Sales Office on (01452) 507458 or contact your local wholesaler.
E-mail: sales@laneshealth.com Website: www.olbas.co.uk



www.laneshealth.com

Our third article, looking in depth at 'Pharmacy in the Future: Implementing the NHS Plan', examines possibly the most controversial section – on changing the pharmacy contract

Only the best will survive

The Government wants to revamp the NHS contract with incentives to encourage the best pharmaceutical care. But behind the promise of rewards lie veiled threats that today's contractors may not be the ones offering these improved services, and rewards for one pharmacy might impoverish another.

When parliamentary time allows, the Government will introduce legislation to allow a new form of agreement between the NHS, pharmacists and pharmacy owners. Pharmaceutical services will be provided under locally tailored arrangements, similar to personal medical services and free from the restrictions of the rigid national remuneration system.

Once the legal framework is in place, the Government will invite proposals from health authorities for pilot schemes to test innovative ways of contracting for pharmacy services. As well as dispensing, these services could include medicines management, health promotion and disease prevention, all within a single agreement.

For the first time, agreements will be possible with individual named pharmacists as well as pharmacy owners. Services will be designed with patients' needs in mind. "And pharmacies will be rewarded according to how well they meet those needs, not just for doing what every other pharmacy has to do," the strategy document states.

The Department of Health will discuss with the Pharmaceutical Services Negotiating Committee changes in the terms of service and distribution of the global sum to establish minimum standards and reward high-quality services, not just volume of prescriptions. Pharmacies providing the best services will gain at the expense of those that are prepared only to provide the minimum.

Speed, efficiency, clinical quality of services, premises standards, the provision of private consulting areas, good record keeping, patient



Pharmacists will have to accept some change is now inevitable

information, continuing professional development and clinical governance will all be taken into account.

"No pharmacy should have the option of standing still while standards elsewhere are rising."

Seeds of doubt

Andrew McCraig, Croydon Local Pharmaceutical Committee secretary, regards the proposals with suspicion. There is no promise of investment to help pharmacies improve. Instead there are hints that the Government could impose further requirements on pharmacies before they can receive a basic practice allowance. Pharmacies with the best facilities, including private consultation areas, could receive a higher allowance, while the rest might receive less than they do now. All this could be done under the present contract without the need for primary legislation.

He doubts whether parliament would regard pharmacy as a high enough priority to devote time for legal changes in the near future.

"My increasing feeling is that pharmacy has never reached the top of the political agenda because we perform well and there are few complaints about us, compared with hospitals that have bodies lying around on trolleys, doctors who kill people and surgeons who cut off the wrong limbs," he says. In real terms pharmaceutical expenditure has fallen below other sectors of the NHS. Contract changes would result in more money being spent and the general attitude is "if it ain't broke don't fix it".

He suspects the strategy document is a sop to satisfy the pressure groups in pharmacy. He sees it as a wish list that recognises what pharmacists should be doing, without providing an

adequate and fair structural and financial framework to achieve the goals set out.

"I don't see the contract changing in my lifetime [he's 52] unless we're going to be bullied into satisfying more conditions before we qualify for the basic practice allowance."

Wally Dove, PSNC chairman, agrees that slots for primary legislation will be precious in the run-up to the election, so he doubts whether much, if any, of the strategy will be implemented during the Government's current term.

"The controversial areas are likely to be left until after the next election," he believes.

On the chances of increased funding, he says: "As always PSNC will be keen to get more money into the equation. But we have to be realistic

Continued on P24 →

**THEY'RE
BACK!**

By popular demand, and they're ready for action
-soothing action



The **Big Softie**

A soothing-action packed £2.1 Million Blockbuster

They're big, they're soft and they're back. Big Throaties soft medicated pastilles are back on the Big Screen. The superb 30 second commercial gained rave reviews from customers on its last showing. So, prepare yourself for big returns.

Original soundtrack available. Certificate

U



IN CINEMAS FROM DEC 2000 - MAR 2001

Driving You Forward



WIN a £20,000

Business Development Grant!

to drive your business forward. We have a wide range of items to spend the fund on, such as this Clio mini van. Whatever your ideas, there will be a team of specialist advisors to ensure you get the most from your prize.



PLUS WIN £1,000

of Thomas Cook Holiday
Vouchers with our
free prize draw.

SB

NiQuitin CQ™ Nicotine CLEAR


UniChem
Delivering Healthcare



THE CLEAR CHOICE

PLEASE SEE PAGE 88 OF THE UNICHEM DECEMBER PROMOTIONS BOOK FOR PRICING DETAILS.

→ Continued from P20

and this part of the strategy will need a lot of detailed discussion."

Talks have already started with the Department and he expects there will be several meetings before any agreement is reached.

What does he think might happen to single proprietors who have done their best to provide an efficient service, with good record keeping, clinical advice and so on, yet who find they simply do not have the time to offer extra services? Would they be penalised because they just "did what every other pharmacy has to do?"

Mr Dove says: "The inference is that the opportunity to develop other services is there, and the single-handed may have to co-operate with others in order to do so."

While acknowledging there is a need to improve standards, he says: "One of the physical constraints is that pharmacies don't have elastic walls. Contractors will have to use their imagination if they are to make substantial changes to their premises, otherwise they risk being left behind."

Liverpool LPC secretary Jeremy Clitheroe was horrified when he first read the contract proposals, because it seemed the global sum would no

longer be ring-fenced for proprietor pharmacists. His fears were confirmed when he heard that the Department of Health intended to implement the pharmacy plan whether or not it had the profession's support. Andrew McKeon, head of the Department's medicines, pharmacy and industry division, told the School of Pharmacy Charter dinner that the aim was to put the plan into effect and hope the pharmacy bodies would help work out the details.

Mr Clitheroe interprets the proposals as requiring all extra services to be funded under the global sum, with no extra money on offer.

"If contractors are not capable of or willing to perform these new duties, the Department is quite prepared to give them to other pharmacists and take the finance from the global sum. The intrinsic value of a pharmacy depends on its profitability, so if this lifeblood is being drained away the goodwill value will be threatened."

PSNC's Wally Dove agrees there could be problems with non-contractor pharmacists wishing to provide services. But it would be too isolationist to try to exclude them. A better option would be to concentrate on making community pharmacy an essential part of the wider world of pharmaceutical services.

Control of entry to go?

The Government will be prepared to change the control of entry rules where there is evidence that they are an obstacle to better services, such as dedicated out-of-hours pharmacies or new one-stop primary-care centres. Control of entry may even be abolished "in places where the restrictions it imposes on competition between pharmacies clearly cannot be justified".

This statement came as no surprise to PSNC's Steve Axon. He told the recent National Association of Co-operative Executive Pharmacists' conference (C&D, October 14, p26) that, ever since the control of entry provisions came into effect some contractors had done everything possible to undermine the regulations or to bend them to their own purposes, purely for commercial gain.

"That is why we have had so many judicial reviews and why we have had so many attempts - albeit unsuccessful - to define a neighbourhood or, worse still, to get around the definition of neighbourhood altogether. The statement in the strategy document could, quite simply, be the Government's solution to the problem set for it by contractors themselves."

The solution, too, was similar to the Royal Pharmaceutical Society's proposal that certain areas should be designated 'open' for the purpose of contract applications.

Mr Axon said it was difficult to argue that control of entry in a shopping complex should differ from that in a rural area unless the concern was convenience and competition rather than access.

"We could end up with a mixture of areas where services are controlled and areas of no control, but who is to say where the line will be drawn?"

One possibility could be for the profession to press for incentives for pharmacy services where they are needed, he said, particularly as the Government is prepared to change the control of entry rules where they are an obstacle to providing better services.

Wally Dove thinks PSNC will have to be realistic and accept that some change is inevitable, because of the many changes outside pharmacy such as shopping habits. Services will have to be where the public want them, he says.

The Royal Pharmaceutical Society's president, speaking at the recent BP Conference, urged the Government to build on the benefits of the existing pharmacy network and not destroy them in any major structural reform.

Christine Glover said: "A large number of our members have invested their entire professional lives and their capital to make the community pharmacy network what it is today."

NOW AVAILABLE FROM ONE DEDICATED NETWORK

SECURE INTRANET SERVICES for the COMMUNITY PHARMACY



NPA.net delivers

- News, current topics, drug alerts and information on shortages
- Web-based Member Services, including Information Leaflets and Listings to download
- PSNCnet, our contractors in England and Wales
- On-line ordering for NPA products and services WEBNFT for free (available 3rd November 2000)
- Martindale on-line by subscription (available 2nd November 2000)
- Pharmacy business intelligence from the IntraPharm network
- Secure Internet access and use of e-mail from the pharmaceutical sector
- Information on future e-pharmacy developments

10th Floor, 100 Grosvenor Gardens, London SW1W 0HN

Tel: 01858 421333

PSNCnet is a web-based information system for National Pharmacists

SECURE INTRANET SERVICES for the PHARMACY COMMUNITY



PSNC.net delivers

- Drug Tariff Part VIII on-line
- Prescription Statistics
- Generic Shortages
- NHS Regulations
- LPC Constitutions
- PSNC News
- Event Calendar
- Secure Annual conference (Nov 2000)

Pharmaceutical Services Negotiating Committee, 59 Buckingham Street, Aylesbury, Bucks, HP20 2EJ

FREE registration. Calls charged at Local Call rates. For a FREE installation CD and password please contact 020 8357 5757

NPA.net and PSNC.net are part of the CDRG network

In the second article in the series John Kerry takes a look at the previously prepared SWOT analyses, with the objective of proposing ways of prioritising and evaluating them for the future good of the business

There is no standard formula for looking at a SWOT analysis, since each business has to be treated individually. No two will have identical characteristics and influencing properties. It is therefore not possible to cover all strengths, weaknesses, opportunities and threats, but some of the more common ones and methods of dealing with them are discussed.

Strengths

The task after compiling your list is to put the points in priority order, according to their value to the business.

At the top of the list, should they be on it, come location and service levels.

Location: A prominent main street position will normally have a large passing traffic. The passing traffic has to be turned into passing trade and regular customers. A location close to the GP's surgery is a major strength and indeed opportunity, but only if the heavy volume of potential prescription patients are looked after well. Many pharmacies forget that patients are also customers. They concentrate too much on delivering a slick dispensing service, while failing to persuade their patients to buy anything.

If it is your main strength, location can also be included in the opportunities list, if there is potential for further exploitation.

Service Levels: Good service levels are becoming just as important as good locations and many a pharmacy is building its business at the expense of its better located competitor, because it provides a better service. Don't be fooled into believing that your business is providing just what the customer wants and therefore giving your service level a higher mark than it deserves. If you are not sure about this aspect it is a topic for the customer-research work that will be dealt with in a later article.

Size is a strength and certainly an advantage over a similarly-placed competitor in a smaller premises, but only if it is used properly. There are so many instances of a good little pharmacy beating a large one, merely because the larger pharmacy failed to take full advantage of extra space, while its smaller neighbour used good service, good merchandising, layout, lighting and other tactics to best effect.

Staff: A well-trained, highly motivated, knowledgeable, caring, loyal and polite staff are as important as any other aspect. If you can



Jason Bonham

Continued on P26 →

→ Continued from P25

honestly say that yours are, then they are right at the top of the list of strengths.

The Pharmacist: A successful pharmacy business revolves around the pharmacist; one with all of the attributes mentioned above for staff, plus the time and skills to communicate with patients on both a professional and social level is going to win. He or she is a pivotal strength of the business. Any shortcomings need to be discovered and put right.

Customer loyalty: There is no substitute for a loyal customer who has been patronising your pharmacy for so long it has become a habit, it is to be hoped for the right reasons. Customers such as this have two important roles to play in your future success. First of all they bring in friends and family and may persuade them to become your customers too. Secondly, they are your captive audience and if you treat them well and offer them more of what they want or demand, they are the easiest route to increased turnover. These aspects are too often taken for granted and the road to failure is littered with businesses where the true value of a loyal customer base was not recognised.

Weaknesses

Points of weakness are normally within the control of a business and can be overcome.

Poor location: This does not necessarily need to be a total drawback. Many pharmacies have successfully countered a poor location by building on other strengths, such as service, product range, size, decor and fittings, prices etc. Advertising and marketing campaigns will help if you have something special to offer when you persuade customers to visit your shop for the first time.

If your pharmacy's turnover is suffering because it simply is not in the right place to pick up either passing trade or patients with prescriptions and you do not believe that any kind of external advertising or marketing activity will change this situation, relocate.

Poor Service: If you know that you service is poor or have discovered through research that local people regard it as such, there is only one solution.

Small Shop: If you operate from a cramped, unwelcoming, inefficient pharmacy you are probably driving customers into your competitors' arms. Building backwards, sideways, taking over the unit next door or minor relocation have worked well in the past.

Staff: Is any member of your staff frightening customers away because of their attitude, lack of knowledge or inability to communicate? Don't let this problem fester. A customer's first contact with your business is a member of your staff. If that contact is unsatisfactory, it may be the last and the customer will influence his or her friends. Nothing spreads faster than a bad reputation.

If you are unable to bring your staff up to a satisfactory level of training, make use of professional trainers, particularly those within the profession.

Pharmacist: Have you discovered or do you believe that you, or your pharmacist manager, are the weak link in the business? This is a problem that has to be tackled with the same vigour as you would a weak member of staff. Quality training is available from a number of bodies within the profession and courses are available from the DTI and other professional institutes.

Shop layout and decor: Often a pharmacy proprietor knows that aspects of the environment, such as front shop layout, fittings and decor need to be improved, but does not want to contemplate the upheaval associated with change. However, because remedying this weakness will improve the retail environment, attract customers and increase counter sales, it has to be done. It does not always entail an expensive refit and if you cannot handle all of the planning aspects, ask someone who can.

It is important that weaknesses are identified by objective observation or research and then eliminated or minimised, to prevent them from discouraging customers from patronising your pharmacy.

Opportunities

Opportunities, large and small, are always there, but some need to be identified. Once evaluated and like strengths prioritised, their exploitation become part of your over-all marketing plan. Keeping a diligent watch on your local market, being aware of changing fashions and demands, listening to customers and carrying out local consumer research, will ensure that few opportunities will be lost.

When strengths are developed and built into the business, proprietors have the opportunity to build upon and exploit them. It is not good enough to have a list of strengths if the business does not have the accompanying opportunities to use them. For example, a 2000 sq ft shop has little value in a tiny village off the beaten track. It is the combined strengths that matter.

Your list of opportunities is likely to be a short one, but it can potentially be expanded by customer and market research. However, the

wise don't wait for opportunities to come along, but make good of the few lesser, but nevertheless significant ones that do present themselves.

For example, a four-GP health centre could be moving closer to your pharmacy; a major housing development with service shops may be planned for your town; a competitor could be closing or up for sale. When opportunities such as these

"There is no substitute for a loyal customer who has been patronising your pharmacy for so long it has become a habit"

arise, you should be ready to take advantage of the chances they offer.

Local market and customer research may reveal other opportunities, such as demand for new products or services which could fit into your business, or dissatisfaction with an existing retailer. Smaller opportunities like these are more likely to present themselves.

Threats

The above major opportunities can easily turn into threats should one of your competitors take advantage of them. Threats, which are largely beyond your control, can be viewed as milestones in your decision-making process. It could be the new shopping precinct 500 yards away, with free parking and a large multiple pharmacy planned for next year, or the four GPs next door are moving to a new health centre across town.

Other examples could be the car park behind your pharmacy is going to be built on and the council is painting double yellow lines outside your premises. Or the nearby supermarket has purchased one of your colleague's businesses and relocated it in the store.

Most threats are not of a potentially catastrophic nature, but local short to medium term problems that must be dealt with. Very often they involve competitive activity, such as a bright new cut-price drug store, a competitor selling all-in-ones at half price, a new mini lab across the road, nearby shops going out of business, or the relocation of a major customer puller (eg Post Office).

These are all problems, but threats of this type will rarely prove fatal.



Jason Bennett

List specifications

Against each and every one of the strengths, weaknesses, opportunities and threats you have listed should be one or more specific activities designed to maximise or minimise them.

It is rarely possible to produce for each an answer that you are confident will work. It is always a good idea to consult a friend or seek professional help, particularly on activities which are either expensive or have an important bearing on the prosperity of the business. Nobody gets everything right and errors can prove costly.

Guess work has no part to play in this process. So for all of the gaps in your plan, all of the questions which remain unanswered and the activities you are planning, minimise or eliminate the risks of getting it wrong by carrying out research. Of which more in the next article, which will look at methods of setting up customer research projects.

The easy way

to train your medicine sales assistants

CAMBRIDGE COUNTERPART

Why pay more?

ambridge Counterpart is:
exible
ffordable
asy to join
asy to use

You could pay more
than double for other
courses
and remember,
Cambridge Counterparts
get instant results on the



assistants must now be trained
Royal Pharmaceutical standards

Are all your employees trained?
What about new, part-time and
Saturday staff?

counterpart is recognised by the Society and accredited through the College of Pharmacy Practice

Fill in the form now to get a complete set of training modules, questions and a briefing pack for just £17.63 (inc VAT). Each pack covers up to four assistants.

Each assistant must be registered for telephone marking and CPP certificate at a cost per person of just £29.38 (inc VAT). List each candidate by first and last name



Pharmacist	
Pharmacy	
Address	
Post Code	
Telephone	
Fax	
Name	£
Sub total	£
Please include () complete sets of counterpart modules 1-14 at £17.63 each (inc VAT) £	
Total £	
<p>Make cheques payable to United Business Media and send to Mary Prebble, Pharmacy Editorial Projects, Chemist & Druggist, United Business Media, Sovereign Way, Tonbridge TN9 1RW</p>	

For further information contact Mary Prebble on 01732 377269

Lib Dems propose central drugs purchasing agency

The Liberal Democrat's Shadow Health Secretary, Nick Harvey, has proposed a central drugs purchasing agency which, he says, could save the NHS £3.4 billion over five years.

Writing in *The House Magazine* - a parliamentary monthly - the MP for North Devon said that, despite the National Plan's efforts to co-ordinate the nation's healthcare, there were many areas that still needed to be addressed.

Pointing to the UK's £7 billion annual drugs bill, he wrote: "and yet pharmaceuticals are purchased in a kind of arrangement that now belongs in smoke-filled rooms."

He felt that a centralised drugs-purchasing agency would bring "accountability and transparency to the murky world of pharmaceuticals" and would "generate enough savings to end the lottery of postcode prescribing".

Waiting for Godot

The Community Pharmacy Action Group was in high spirits this week following the Court of Appeal ruling which led to the suspension of the entire panel hearing the resale price maintenance case.

While a lot is going on in the background, CPAG finds itself in "the middle of a vacuum", waiting for the Appeal Court's judgement to be delivered in writing, as well as the next move from the OFT.

"There is always a possibility that the OFT might appeal to the House of Lords to get the original panel reinstated," CPAG said.

CPAG is, however, adamant that it will have the necessary funds to continue despite the delay. The president of the Restrictive Practices Court, Sir Roger Buckley, has indicated that he would like the case to resume in March next year, but CPAG believes this might not be until after Easter.

Best pharmacy assistant award

The search is on for the pharmacy assistant who is simply "one in a million". Independent pharmaceutical wholesaler Mawdsleys is inviting all its pharmacy customers to nominate their Millennium pharmacy assistant, and explain in no more than 40 words what makes their nominee special.

Deadline for entries to the competition is January 5, 2001, and the winner will receive £250 in vouchers from the shop of their choice.

Unichem comes up trumps in *Daily Telegraph* award

Unichem has seen off high calibre competition to win the *Daily Telegraph* Energis Customer Service Award 2000 in the Retail and Distribution category.

Having been shortlisted from originally 242 other public sector companies, Unichem beat established names such as Carphone Warehouse, Dixons and Iceland Foods into second place in the final stages of the competition.

"Quite clearly to win against tough competition like this and in a customer service award is very pleasing. The important thing is that we had an outside company [Energis] effectively tell us that we excel in customer service," said Martyn Ward, Unichem's sales and marketing director.

Customer care standards were judged on the basis of detailed submissions by the company, customer interviews and anonymous service verification checks. The panel of judges is said to have been particularly impressed with two of Unichem's recent customer service initiatives.

The Counter Attack scheme allows customers to buy OTC products in splits. Peter Skinner, Unichem's marketing controller, believes that the scheme can potentially help pharmacists win back some of the lost OTC sales by getting the stock levels right, alongside the right merchandising and right promotions.

Spoc, or single point of contact,

ensures that customers can speak to the same customer service clerk every time, thus building up a personal relationship. Customers will also receive a weekly phone-call from their 'spoc' to check everything is working alright.

After celebrating the award, internal and external communications are Mr Ward's next priorities. "Communicating our success to our staff is important. This is not a head office award - every branch, every depot and every van driver has had a part in it," he said.

UniChem has arranged a deal with Southern Electric that it claims will enable pharmacists to save up to £64 a year by switching to the electricity supplier. The saving is based on an average energy consumption of less than 12,000kW per year, equivalent to an annual bill of around £1,000. Pharmacists with higher bills can save up to 20 per cent, according to UniChem. For more information call Southern Electric on 0845 6000 661 and mention UniChem.



Unichem's winning team at the *Daily Telegraph* Energis Customer Services Awards. From left to right: Kevin Hussey (Energis), Peter Skinner (Unichem's marketing controller), gala host Fiona Bruce (BBC News and Crimewatch presenter) Christ Etherington (managing director Unichem), Geoff Mellor (Unichem's depot manager at Hinckley), Martyn Ward (Unichem's sales and marketing director)

FSB bails out its flood victims

Pharmacies affected by the recent floods may be eligible for a grant of up to £500 if they are members of the Federation of Small Businesses.

The grants are available to help businesses continue trading and can be used towards the costs of temporary private or business accommodation. Members who are uninsured and

have lost everything will be considered for small lump-sum payments.

The organisation has made £20,000 available to each of the seven regions that were affected most by the floods. These include: Kent; East Sussex; Western; South, West and East Yorkshire; North Yorkshire; Shropshire, Herefordshire and

Worcestershire; and North Wales regions.

The FSB estimates that it has about 800 pharmacy members. Pharmacists whose businesses were affected by the floods should apply to their local FSB region in the first instance. More information is available at www.fsb.org.uk.

COMING EVENTS

DECEMBER 4

Bristol Branch, RPSGB, at the BAWA Leisure Centre, Filton, 7.30 for 8pm. 'IT and Pharmacy - an opportunity for excellence' by Ian Shepherd, information management and technology, RPSGB.

East Kent Branch, RPSGB, at Howfield Manor, Chatham, 7.45pm. 'Reflexology - a demonstration' by Gillian Soutar, MAR.

Eastbourne Branch, RPSGB, Sara Hampson Room, Eastbourne DGH,

8pm. 'Assisted Fertility - what's new?' by Mr D Robertson, FRCOG, director of the Assisted Conception unit, Esperance Hospital, Eastbourne.

DECEMBER 5

Bath Branch, RPSGB, Pratts Hotel, Bath, 7.30 for 8pm. 'National Service Frameworks for Coronary Heart Disease' by Denise Taylor, University of Bath.

Northern Scottish Branch, RPSGB, 7.30pm. 'Tour of Scientific Support Unit, Northern Constabulary, Inverness'.

DECEMBER 6

Stirling and Central Scottish Branch, RPSGB, at the Royal Hotel, Bridge of Allan, 7.45pm. 'A Journey to Bolivia' by Peter Record, committee member.

DECEMBER 7

Lanarkshire Branch, RPSGB, at the Strathclyde Hilton Hotel. 'Quiz Night'.

DECEMBER 7 and 8

NICPPET, at the White Gables Hotel, Hillsborough, 10am-5pm. 'Research Methods in Clinical Practice'.

When Kirit met Tony ...

Possibly the most famous doors in Britain opened for at least one pharmacist this week as Kirit Patel, chief executive of the Day Lewis Group, entered corridors of power.

Mr Patel had been invited to No 10 Downing Street to attend the Prime Minister's seminar on support for small businesses.

Mr Patel told Tony Blair that one of the major problems pharmacy had was that the various government departments often did not seem to pull in the same direction.

"The problem as I see it is that the Government is not as joined up as it makes out to be. On the one hand you have got the Office of Fair Trading and the Department of Trade and Industry trying to abolish Resale Price Maintenance, and on the other hand you have got the DoH/NHSE wishing to extend the role of pharmacists," Mr Patel explained.

Questioned by the Prime Minister on his opinion of the National Plan, Mr Patel congratulated the Government on this document but pointed out that there was no mention of new money being made available.

"The Treasury needs to make a medium to long-term investment to promote pharmacists' role," Mr Patel



Kirit Patel, chief executive of the Day Lewis Group, pictured far left, attending the Prime Minister's seminar on support for small businesses

said. He added that this would not only benefit the healthcare provision in the UK but that eventually the additional spending could be recouped by keeping patients out of hospital with pharmacists' help.

Tony Blair had earlier outlined the Government's plan for small businesses and promised to ease the bureaucratic burden on them by cutting back unnecessary business regulations and simplifying existing ones, and stream-

lining the employment tribunal system. A third measure was the introduction of a new code of practice on written consultations.

The meeting was also attended by Small Firms and e-commerce Minister Patricia Hewitt, Treasury Minister Dawn Primarolo, David Irwin (chief executive of the small business service), Chris Humphries (British Chambers of Commerce) and William Sargent (Small Business Council).

ABPI calls for breathing space from NICE

The Association of the British Pharmaceutical Industry (ABPI) has called for a "window of opportunity" allowing new medicines to be used before they are assessed by NICE (National Institute for Clinical Excellence). The time would be used to collect reliable evidence about the clinical and cost-effectiveness of the drug. The ABPI said this would ensure that NICE's appraisal could then be carried out on the basis of sound data.

The ABPI warned that under the current system there was a real risk that pharmaceutical companies would be increasingly unlikely to choose the UK as the primary market for a product launch, so jeopardising the UK as a base for future Research and Development.

"There is no doubt that new and better medicines will arrive. The big unanswered question is whether British scientists will be encouraged to develop them and whether NHS patients will be able to reap the benefits," said Dr Trevor Jones, ABPI director general.

The ABPI also called for the spending of funds committed to implementing NICE's guidance to be monitored and pressure put on health authorities who use NICE as an excuse not to take up new medicines.

Safeway plans more room for pharmacy

Safeway plans to increase its involvement in pharmacy as part of the company's overall strategy to expand the non-food area of its business, announced last week.

Over the next two years 25 Safeway stores will be converted into hypermarkets which will be created by increasing the selling space of existing outlets.

As medicines and health and beauty products are classified as non-foods, the floor space for these products may also be increased, according to Paul Bennett, superintendent pharmacist.

"In the past, a lack of space has had an impact on the number of pharmacies we have opened. This gives us an opportunity to pursue our ambition to acquire more pharmacy contracts and will help our plans to accelerate the rate at which we open more pharmacies," Mr Bennett said.

"If a store that is being extended already has a pharmacy, this will then give us the opportunity to re-position or expand that pharmacy," he added. Safeway currently has 107 pharmacies.



Boots is planning to open a further 38 Chiropody and Footcare practices by the end of March 2001, investing £6m in the venture. The stores will be situated alongside Boots Dentalcare in existing stores nationwide. The company said the pilot with six such practices had exceeded expectations in terms of hourly income and occupancy rates. According to Boots, 18,000 patients have registered with the chiropody and Footcare practices so far

IMPORTANT SAFETY NOTICE - RECALL

New Karvol Vaporiser

Crookes Healthcare is taking the precautionary step of recalling the new Karvol Vaporiser and Refill, launched earlier this year. The original Karvol Decongestant Capsules and Karvol Decongestant Drops are not affected by this recall.

The Vaporiser has been recalled because of a small number of instances where the refill bottle has been accidentally removed from the plug-in vaporiser unit, allowing direct contact with the liquid. The company is placing recall announcements in national newspapers.

Crookes Healthcare is asking pharmacists/retailers to refund all Karvol Vaporisers and Refills. We will fully reimburse all refunds and returns of remaining stock and ask you to accept all returns without a proof of purchase to ensure a swift recall.

We are committed to providing trusted and reliable products to our customers and apologise for any inconvenience this recall may cause.

If you have any queries, please call our

Customer Helpline on 0800 093 2075

Classified

Appointments £27.00 P.S.C.C. + VAT minimum 3x1. General classified £18.00 P.S.C.C. + VAT minimum 3x2. Box numbers £15.00 extra. Available on request. Copy date 12 noon Tuesday prior to Saturday publication. Cancellation deadline 10am Friday, one week prior to insertion date. All cancellations must be in writing. Contact Debra Thackeray, Chemist & Druggist (Classified), United Business Media Ltd, Savereign Way, Tonbridge, Kent TN9 1RW. Telephone 01732 377493, Fax: 01732 377179. Internet: <http://www.datpharmacy.co.uk>. All major credit cards accepted



For all your Classified Advertising
Please contact:

Debra Thackeray on 01732 377493

CHRISTMAS DEADLINES

Please note December 23rd and 30th issues will be combined.

The deadline for this is 12 noon on December 19th.

APPOINTMENTS

DULWICH NORWOOD AREA

Dispensing assistant/experienced counter assistant required full or part-time considered for West Dulwich pharmacy.

Please telephone: Mary Williams
after 8 pm on 020 8670 2608

BUSINESS WANTED



CHEMIST
We Care



Progressive chain of 60 shops seeks to acquire Pharmacies with turnover of in excess of £400,000 in Southeast England and East Anglia. Freehold purchases. Matter treated in the strictest confidence. For a quick decision contact:

Day Lewis Group, Bensham House,
324 Bensham Lane, Thornton Heath, Surrey CR7 7EQ
Tel: 020 8689 2255 ext. 221. Mobile 0860 484999.
Fax: 020 8689 0076 Email: DayLewis@aol.com

C.C.T.V

CCTV SALE

Colour Quad System

4 Cameras, Quad Split
24hr VCR, 14" Screen
£1099 - 7 units available

WHOLESALE DISTRIBUTOR

Colour Multiplex System

4 Cameras, duplex, Multiplexers,
24hr VCR, 14" Screen
£1499 5 units available

Many other products available

Free Call 0800-056 0462

WEBSITE: WWW.SECURITYDIRECT.CO.UK

LOCUMS

NEED A LOCUM?

Employers Stop paying expensive agency fees.

We supply locums for only £5 per day booking fee. Your vacancy can also be sent on-line to visiting locums using the largest e-mailing lists in the UK.

All areas. Also view available dates.
Many successful bookings.

Locums - simple to join a list.
Visit: www.locumline.co.uk
e-mail: locumline@globalnet.co.uk
Phone: 07790 649346
Fax: 01923 333231

Site update: Recent vacancies: 215
Locums receiving vacancy e-mail alerts: 640

LOCUM PHARMACIST

AVAILABLE

- Based in South Wales/West
 - Will travel nationwide
 - Taking bookings for January now
- Telephone: Justyn 0771 5061143**
email: justynmurphy@ukonline.co.uk

PRODUCTS & SERVICES



MANUFACTURERS OF SPECIAL PHARMACEUTICAL PRODUCTS

Bespoke Tailors of Pharmaceuticals offering

A TRADITIONAL SPECIALS SERVICE

for that "specials" patient cared for by that special professional

Where confidence in quality and price is a must and where the minimum order value is ONE.

Contact:
Karol Pazik, Director, on 01296 394142.
Mandeville Medicines, The Specialists in Specials.
For sterile, non-sterile and assembled specials,
clinical trials supplies and a free help line.

Mashco Plc

National Distributors of Photo & Electrical Products

Special Offers

BRAUN/ORAL-B PLAQUE REMOVERS



D6011
Braun Oral-B Plaque Remover
RRP £19.99 to £14.99
Invoice Price £8.98
Net Price

2
OFFER

£8.75
NET INV

3 D15

1/2 Price offer

3
OFFER

£14.50
NET INV

Tel: 020 8204 2224 Fax: 020 8204 0224

Email: enquiries@mashcoplc.com

Subject to availability

E&OE

Net prices are after settlement discount of 2.5%



"By sourcing throughout the EC and having carefully controlled overheads, I can save you money over other UK trade photographic prices.

All my stock has identical or near identical UK packaging, indeed over 50% is bought from official UK distributors. It is also fresh and has been correctly stored.

With 23 years of trade experience I will save you money on the stock you want.

Give me a call, fax or email."

JEFF SCOWEN

PHOTOGRAPHIC WHOLESALERS

UNIT 4 HITHER GREEN CLEVEDON BRISTOL BS21 6XT
TEL 01275 87 22 55 FAX 01275 87 22 66
sales@jeffscowen.com www.jeffscowen.com



PHARMACEUTICALS PLC

Call Now for great offers on our
New Innovative Products
25% Bonus stock if you spend £80 or more



Breatheaze Breath Freshener Spray



Available in Unique Flavours:
Cinnamint,
Mint Chocolate,
Wintermint,
Spearmint and
Peppermint*

Breatheaze £21.81 Pack Size 24

Replicas of famous brands:
Tommy
Obsession
Chanel No 5
Polo, CKOne
Cool Water and Paco
Rabanne*
*Selection supplied may vary

Impressions Perfumes and Colognes

A1 Pharmaceuticals PLC,
Unit 3 Bessemer Park Industrial Estate,
250 Milkwood Road, Herne Hill, London SE24 0HG
Freephone: 0500 295329 Fax: 0800 074 1983

NEW PRODUCT ANNOUNCEMENT

Co-pharma Heel Balm

*Unique Triple Action Treatment for
Dry Cracked Heels*

NOTICEABLE IMPROVEMENT WITHIN 7 DAYS

Dry, cracked skin (xerosis) is a common condition involving the thickening and fissuring of the underneath and outer margins of the heels. The condition can also affect the soles of the feet, undersides of the toes, elbows and knees. In addition to being unsightly, if neglected, untreated cracks may deepen to the extent that the dermis layer of the skin is affected and may lead to painful and more serious problems, including infections.

Co-pharma Heel Balm contains high strength Urea (25%) and Allantoin, powerful Keratin softening agents, which work by chemically breaking down hard, thickened areas of skin, aiding its easy removal.

Moisturisers penetrate deeply into dry skin to increase water uptake, allowing dry skin to be replaced by soft, healthy skin.

Natural Peppermint Oil aids in leaving feet feeling fresh and cool. Will also help prevent blisters.

Co-Pharma Heel Balm is now available from all wholesalers.

PIP CODE 269-0949

AAH CODE COP 328H

Retail £5.99/100G

Tel: 01923 255580



R.R.P. £19.99 each

Trade prices available

Lavender enhanced Wheatbag insert means you can use him like a hot water bottle - without any of the dangers.

After just two minutes in the microwave, the Wheatbag insert will transform this adorable bear and Pup into the most delightfully calming warm cuddly toy.

Both of these high quality toys fully comply CE with Regulations and have also been tested by the B.S.I.

For further information:

The Original Wheatbag Company Ltd PO Box 437, Woking, Surrey GU21 4FU

Tel: 01483 598483 Fax: 01276 855564

E-mail: info@wheatbag.com www.wheatbag.com



Co-Pharma Tel: 01923 255580

CAMRx

BUYING GROUP

How do you unleash profit power within your business and maximise results?

Two mainline wholesalers listed as suppliers to CAMRx members

Interested?

Call Pauline NOW on FREEPHONE
0800 526074

*****4 MONTHS FREE TRIAL MEMBERSHIP*****

Mr R. L. Hindocha
BPharm.MRPharmS.FInstD.
54/66 Silver Street, Whitwick,
Leicestershire LE67 5ET

White & Luckman
Stocktakers and Business Agents
(Established 1946)

Telephone: 0121 708 1530
Fax: 0121 708 1560 Mobile: 07801 847359

**41 Warwick Road, Olton,
Solihull, West Midlands B92 7HS**

SHOP FITTINGS

**Complete pharmacy shop fittings for sale,
includes dispensary, perfume cabinets,
gondolas etc.**

Best offer secures

Please Telephone Mr Rai:
0208 845 9522

BUSINESS LINK

A free service for C&D subscribers

Free entries in 'Business Link' (maximum 30 words) are restricted to community pharmacist subscribers to *Chemist & Druggist*. No trade advertisements will be permitted. Adverts must be submitted on the coupon (right), which must be properly completed, and include an expiry date for products. Acceptance is at the discretion of the Publishers and depends on the space available. Pharmacists should only advertise medicines for sale where the product is discontinued or in short supply. Medicines must be unopened and in original packaging.

To: Business Link, CHEMIST & DRUGGIST, Sovereign House, Sovereign Way, Tonbridge, Kent TN9 1RW.

PLEASE COMPLETE IN BLOCK CAPITALS

Surname

First names

Address

..... Postcode

Personal RPSGB Registration number.....

Telephone Number

Proposed advertisement copy (maximum 30 words)

.....

.....

.....

.....

.....

.....

.....



Promoting Animal Health through Pharmacy

*Gallop Along Compete with
the mail order horse wormer houses*

Equitax (oxibendazole)

Buy two get one free!!!!!!

**Brian G. Spencer Ltd
19-21 Ilkeston Road, Hleanor,
Derbyshire DE75 7DT**

Tel: 01773 533330 Fax: 01773 535454

Freephone: 0800 387348

Vat Reg. No. 100 0738 36

Ulster Chemists have a ball!

Ulster pharmacists were on their best behaviour last weekend - it was, after all, the Ulster Chemists Association Ball at Belfast's Europa Hotel. "It's our 15th wedding anniversary next month," confided one allegedly hard-done-by wife. "You'd have got out a lot earlier if you had signed up to the Good Friday agreement sooner," was the deadpan response from a passing colleague.

Journalists perked up for a potential news story when NPA director John D'Arcy briefly became interested in Zen and the art of motorcycle maintenance. He had won a prize in the raffle - Be an Easy Rider for a weekend on your own Harley Davidson'. Wife and Mallinson House forgotten, you could see his eyes mist over and his wrist flex on the throttle. Unfortunately he crashed and burned at the first bend as the offer had to be taken up locally. Still, the 20in colour television he took away instead will fit well in the office.

With it being the weekend after Thanksgiving (a pagan US festival), there was an American theme. Bill and Hillary were doing the rounds, and Mickey was much in evidence.

UCA president Fiona Harte encouraged pharmacists to "jump together" with a united front to face the challenges ahead, and warned that the UCA soon hopes to establish itself on the information superhighway. And, finding herself short of a guest speaker, she paid a poignant tribute to the late Ronnie McMullan.

Meanwhile the raffle raised £1,415 for CRISP, a charity which supports parents of children who suffer from cerebral palsy.



Numark's Terry Norris links arms with some colourful local characters



NPA director John D'Arcy with UCA president Fiona Harte

Adam Smith knew all about RPM in 1776

Thanks to the Scottish Pharmaceutical Federation, we are reminded about the prescient writings of an eminent economist, Adam Smith.

Hailing from Kirkcaldy, Fife, where the current Chancellor, Gordon Brown, grew up, Adam Smith wrote the great treatise on economic liberalism, the 'Wealth of Nations'. Published in 1776, the work looks at economic freedom and has been adopted as the basis of free enterprise.

An interesting passage in the book relates to the humble apothecary.

"Apothecaries' profit is become a bye-word, denoting something uncommonly extravagant. This great apparent profit, however, is frequently no more than the reasonable wages of labour. The skill of an apothecary is a much nicer and more delicate matter than that of any artificer whatever; and the trust which is reposed in him is of much greater importance. He is the physician of the poor in all cases, and of the rich when the distress or danger is not very great. His reward, therefore, ought to be suitable to his skill and his trust, and it arises generally from the price at which he sells his drugs."

"But the whole drugs which the best employed apothecary, in a large market town, will sell in a year, may not perhaps cost him above thirty or forty pounds. Though he should sell them, therefore, for three or four hundred, or at a thousand per cent profit, this may frequently be no more than the reasonable wages of his labour charged, in the only way in which he can charge them, upon the price of his drugs. The greater part of the apparent profit is real wages disguised in the garb of profit."

Were these words repeated at the Restrictive Practices Court in the resale price maintenance hearing, we wonder?




Mini-marathon man

If you're going to run your first half marathon, you can't do much better than the Great North Run. So congratulations to pharmacist Grahame Rowley, who raised £760 for Francis House, a children's cancer charity in Didsbury, Manchester. Mawdsley-Brooks generously agreed to sponsor him for the event. "At 10 miles there was a huge hill to climb but when you know that there is a lot of money for charity at stake you know that you have to keep going - you know you've got plenty of time to recover afterwards," says Mr Rowley. "It was an absolutely fantastic atmosphere, and that helped too."

Philip Bradley, Mawdsleys' marketing manager, says: "We are pleased to hear about our customers' charity efforts and congratulate Grahame on completing his run."



A company's history is often so dry that it barely gets a glance. The Bayer Tapestry (with apologies to 1066 And All That) presents a unique solution to the problem. As it is 12ft or so, we cannot reproduce it all, but this section gives a flavour. "Bayer cannot claim great antiquity ... nevertheless our history remains a rich tapestry of invention, discovery and positive development that goes beyond science, chemistry and research into all our daily lives." Say it with pictures is definitely our recommendation!



CHEMIST & DRUGGIST

DIRECTORY 2001

ALSO TABLET AND CAPSULE IDENTIFICATION GUIDE

A must have for....

- ... Community Pharmacists**
- ... Hospitals**
- ... Pharmaceutical & Healthcare Manufacturers**

If you need to...

- Spend less time looking for suppliers and more time getting the best possible deal.
- Help your customers by putting them in touch with the most appropriate organisation or association.
- Get in touch with your local pharmaceutical committee or NHS office.
- Track down the nearest pharmaceutical wholesalers.
- Target potential customers, be they community pharmacists, hospitals or wholesalers.

And only have time to look in one place!

Chemist & Druggist Directory 2001 has contact information on over 10,300 market specific companies. Including listings of pharmaceuticals & chemicals, pharmaceutical equipment, supplies & contractors, retail pharmacy supplies, brands & trade names, wholesalers, hospitals, NHS offices, associations and organisations. Plus, industry specific Statutory & Voluntary Controls and the unique Tablet & Capsule Identification Guide.

To find out more, or to order your copies call 01732-377-591, fax 01732-377-479, or email orders@unitedbusinessmedia.com quoting C&D or click on www.ubminfo.co.uk.

United Business Media, Riverbank House, Angel Lane, Tonbridge, Kent, TN9 1SE

Tel: 01732 377591 Fax: 01732 377479

Email: orders@unitedbusinessmedia.com

www.ubminfo.co.uk

We wish you a happy Christmas and a prosperous new year



To guarantee you get all your pre-Christmas deliveries in time



Don't leave it too late to place your orders



RETAIL & HOSPITAL Customer Orders

Orders placed by close of business on **20 December**
will be delivered before 24 December

Orders placed from the **21–23 December**
will be delivered from 29 December onwards

WHOLESALE Customer Orders

Orders placed by close of business on **15 December**
will be delivered before 24 December

Orders placed on the **16/17 December**
will be delivered on 29/30 December onwards

Orders placed from **20 December**
will be delivered from 4 January 2000 onwards

Call us on **0800 697311**

NORTON
Healthcare

in time **for Christmas**